header logo image


Page 669«..1020..668669670671..680690..»

Migration is increasing regional differences in genetic factors associated with the ability to learn – PsyPost

March 8th, 2020 10:46 am

Recent socio-economic migration within the United Kingdom has influenced the geographic distribution of human DNA linked to traits such as education levels and health, according to a new study published in Nature Human Behaviour.

We were interested in looking at the geographic distribution of human DNA. I have studied the geographic distribution of genetic ancestry differences before, but not yet the geographic distribution of the genetic predisposition to heritable traits and diseases, said lead author Abdel Abdellaoui of the University of Amsterdam.

UK Biobank provided a dataset that was large enough to have a look at this, so we did for more than 30 traits and diseases, including physical and mental health, personality, and educational attainment.

Drawing on data from 488,377 people of European descent surveyed for the UK Biobank, the researchers examined about 1.2 million genetic variants to calculate the polygenic scores an estimate of someones genetic predisposition for a certain characteristic for 33 measures related to economic, health and cultural outcomes. These included but were not limited to physical and mental health, religion, addiction, personality, BMI, reproduction, height and educational attainment.

The researchers found that 21 traits showed significant regional clustering on a genetic level after controlling for ancestry. The findings suggest that regional differences in educational attainment genes are the result of more recent selective migration within the country.

When looking at regional differences between genes for a wide range of traits, genes that are associated with educational attainment show the largest regional differences in Great Britain. These differences are increasing over time, as higher educated individuals leave the poorer regions of the country. These poorer regions show worse living circumstances than the rest of the country, which contributes to worse health outcomes in these regions, Abdellaoui told PsyPost.

The researchers noted that people tend to migrate to improve their skills or employment prospects. In the late nineteenth and early twentieth century, for example, many people left small farms to work industrial jobs in urban centers.

This study has scientific as well as societal implications. There are several widely used study designs that assume that genes are randomly distributed across geography, which we show is not the case. Also, we should take better care of the poorer regions of the country, since the poor living conditions there are causing these regions to have worse health outcomes and are driving talented people away, which is increasing genetic differences between poor and rich, Abdellaoui said.

Our research shows that people have polygenic scores that are more similar to their neighbours polygenic scores than to those of people who live far away. While some of this clustering could come from ancestral differences, we find some of it seems to have a more recent origin. And, when we look at how our subjects have moved during their lifetime, we can see that this clustering is increasing, added co-author David Hugh-Jones in a news release.

There are a few caveats, however. The genetic effects on educational attainment are difficult to quantify, because the genetic predisposition for lower education coincides with worse living conditions that also have a detrimental effect on educational outcomes. Within family studies may offer a solution for this, which is something we are currently working on, Abdellaoui explained.

The study, Genetic correlates of social stratification in Great Britain, was authored by Abdel Abdellaoui, David Hugh-Jones, Loic Yengo, Kathryn E. Kemper, Michel G. Nivard, Laura Veul, Yan Holtz, Brendan P. Zietsch, Timothy M. Frayling, Naomi R. Wray, Jian Yang, Karin J. H. Verweij, and Peter M. Visscher.

Read this article:
Migration is increasing regional differences in genetic factors associated with the ability to learn - PsyPost

Read More...

$100 Genome Sequencing Will Yield a Treasure Trove of Genetic Dataand Maybe a Dystopian Nightmare – Singularity Hub

March 8th, 2020 10:44 am

What would the implications be if decoding your genes cost less than a pair of designer jeans? We might soon find out after a Chinese company claimed it can sequence the human genome for $100.

The speed at which the price of genetic sequencing has fallen has been astonishing, from $50,000 a decade ago to roughly $600 today. For a long time, the industry saw the $1,000 genome as the inflection point at which we would enter the genomic agewhere getting a read out of your DNA would be within reach for huge swathes of the population.

That milestone has come and gone, but progress hasnt stopped. And now Chinese firm BGI says it has created a system that can sequence a full genome for just $100. If the claims hold up, thats a roughly six times improvement over state-of-the-art technology.

The key to the breakthrough is a significant increase in the size of the chip that is used to analyze genetic data, so twice as many genomes can be processed at once. Their machine also uses a robotic arm to dunk the chip into baths of the chemicals used to carry out the sequencing process, which allows them to be reused multiple times.

The company says the system, which will be made available to customers late this year, is aimed at large-scale genomics projects and could make it possible to decode the DNA of 100,000 people a year.

The breakthrough could spur further price falls as well, by breaking the stranglehold that industry leader Illumina has had on the market. Dennis Grishin, co-founder of startup Nebula Genomics, told MIT Tech Review that he believed the reason the price of genetic sequencing had remained stuck around $1,000 in recent years was due to Illuminas near monopoly.

A $100 genome could significantly broaden the scope of what we can do with genetic data. The growing field of population genetics promises to uncover the genetic quirks that set different groups of people apart, which can prove vital for developing new medicines and understanding the susceptibility of different groups to certain conditions.

While some ambitious projects, such as the UKs biobank project aimed at collating genetic data on 500,000 people, are already underway, the cost of sequencing has so far limited the scope of these projects. A dramatically cheaper system could see these kinds of initiatives become far more commonplace, greatly expanding our understanding of genetic diversity among humans.

By bringing the cost of full genome sequencing within reach of everyday people, the approach could also dramatically expand the scope of personalized medicine. While services like 23andMe have seen a huge expansion in consumer genetic testing, these services only decode a small fraction of the genome that isnt particularly useful for medical purposes.

DNA sequencing is already used to tailor cancer treatment by determining how peoples genetics are likely to influence their response to certain treatments, but it is still far from standard practice. At $100 the practice could become far more common and also be expanded to predict responses to a host of other treatments, ushering in a new era of personalized medicine.

Theres also hope that it would enable new tests that could provide early warning of susceptibility to a host of genetic diseases, or even sequence the DNA of patients microbiomes to detect imbalances in their gut flora that might be responsible for certain conditions or impact their responses to certain treatments.

Rade Drmanac, chief scientific officer of Complete Genomics, a division of BGI, told MIT Tech Review that at $100 it could soon be common to sequence the DNA of every child at birth. This could provide unprecedented early-warning for a host of diseases, but would also open up a Pandoras box of ethical concerns.

The movie Gattaca already explored the potential for discrimination when genetic testing becomes trivially easy, particularly when paired with increasingly powerful genetic engineering that is bringing the potential for designer babies ever closer.

Perhaps more importantly though, our understanding of how our genetics impact our lives is still very hazy. While we have identified some genes that strongly influence propensity for certain diseases, most human characteristics are governed by complex interactions between multiple genes whose activity can vary throughout our lives in response to environmental pressures.

Our ability to read our DNA is far ahead of our ability to understand it, which could lead to all sorts of problemsfrom creating a new class of worried well flagged as at risk of certain conditions that never come to be, to unnecessarily medicalizing or stigmatizing patients in ways that alter the trajectories of their lives.

With a $100 genome now within reach, we will have to tackle these issues with urgency to make sure the genomic age is one to look forward to rather than one to fear.

Image Credit: Pete Linforth from Pixabay

Continue reading here:
$100 Genome Sequencing Will Yield a Treasure Trove of Genetic Dataand Maybe a Dystopian Nightmare - Singularity Hub

Read More...

Gut microbes could be key to treating ulcerative colitis – Medical News Today

March 8th, 2020 10:44 am

Scientists have linked a missing gut microbe to ulcerative colitis, opening the door to a possible new treatment.

A team of scientists from Stanford University School of Medicine, California, has identified a gut microbe that is missing in some people. This finding may be key to why some individuals develop ulcerative colitis.

The research appears in the journal Cell Host & Microbe.

The scientists hope that by replacing the function of this missing microbe, it may be possible to develop new and more effective treatments for ulcerative colitis.

The National Institute of Diabetes and Digestive and Kidney Diseases note that ulcerative colitis is a type of inflammatory bowel disease.

It causes inflammation and sores in a persons large intestine, which can result in abdominal pain, weight loss, diarrhea containing pus or blood, and other issues.

The symptoms of ulcerative colitis can range from mild to severe, and there is currently no cure. Instead, treatments focus on keeping the disease in remission for as long as possible.

Treatment usually begins with medications, but if these do not work, surgery may be necessary.

According to the Crohns and Colitis Foundation of America, 2345% of people with ulcerative colitis will eventually need to have surgery.

Surgery involves the complete removal of a persons colon and rectum. The surgeon will then create either a stoma, which acts as an external pouch to collect intestinal contents, or an ileoanal reservoir, which is a J-shaped pouch at the end of the small intestine that does the same job.

Until now, scientists have not been sure why ulcerative colitis affects some people and not others. The new research from the team at Stanford suggests that a key reason may be the lack of particular gut microbes.

Some people who have surgery to create the J-shaped pouch for their ulcerative colitis will then find that inflammation and the associated symptoms return.

Interestingly, people who have the genetic condition familial adenomatous polyposis (FAP), which also requires the creation of a J-shaped pouch, never experience any inflammatory symptoms.

The researchers wanted to work out why this was the case. To do so, they compared two groups of participants, one with FAP and the other with ulcerative colitis, looking for any significant differences between them.

They found that a key difference was the presence of a type of bile acid in the intestines, which was in far greater quantities in those with FAP than in those with ulcerative colitis.

These bile acids are a natural part of a healthy gut and help break down fats.

In the intestines, bacteria convert these bile acids to secondary bile acids.

The scientists were able to identify a specific bacterial family called Ruminococcaceae that was underrepresented in those with ulcerative colitis.

Ruminococcaceae bacteria are the main type of microbe that converts primary bile acids into secondary bile acids.

As Dr. Aida Habtezion, an associate professor and senior author of the study, notes: All healthy people have Ruminococcaceae in their intestines. But in the [ulcerative colitis] pouch patients, members of this family were significantly depleted.

Helping to confirm their findings, the investigators found that stool samples from the participants with FAP turned primary bile acids into secondary bile acids, whereas samples from those with ulcerative colitis did not.

The team then gave acid supplements to mice who had ulcerative colitis to replace any missing secondary bile acids. This reduced inflammation as well as the normal symptoms of colitis in mice.

This study helps us to better understand the disease, says Dr. Habtezion.

We hope it also leads to our being able to treat it with a naturally produced metabolite thats already present in high amounts in a healthy gut.

Dr. Aida Habtezion

To get to this point, the team is now conducting a clinical trial to discover whether an acid supplement can help people with ulcerative colitis.

Read the rest here:
Gut microbes could be key to treating ulcerative colitis - Medical News Today

Read More...

Gates-funded program will soon offer home-testing kits for new coronavirus – Seattle Times

March 8th, 2020 10:44 am

Testing for the novel coronavirus in the Seattle area will get a huge boost in the coming weeks as a project funded by Bill Gates and his foundation begins offering home-testing kits that will allow people who fear they may be infected to swab their noses and send the samples back for analysis.

Results, which should be available in one to two days, will be shared with local health officials who will notify those who test positive. Via online forms, infected people can answer questions about their movements and contacts, making it easier for health officials to locate others who may need to be tested or quarantined, as well as to track the virus spread and identify possible hot spots.

Initially, the lab will be able to conduct about 400 tests a day, eventually expanding to thousands of tests a day, said Scott Dowell, leader of coronavirus response at the Bill & Melinda Gates Foundation. The project is ramping up as quickly as possible, but its not clear exactly when it will launch, he added. Among other things, software needs to be upgraded to handle the expected crush of requests, and a detailed questionnaire finalized for people who request tests.

Although theres a lot to be worked out, this has enormous potential to turn the tide of the epidemic, Dowell said.

While Public Health Seattle & King County has confirmed 71 cases and 15 deaths as of Saturday, modeling by Trevor Bedford, a computational biologist at Fred Hutchinson Cancer Research Center, suggests the actual number of infections in the Seattle area is between 500 and 600. Unchecked, that is projected to increase to 30,000 by the end of March underscoring the importance of slowing the spread as quickly as possible, Dowell said.

The new effort aims to leverage the formidable resources and expertise of the Gates Foundation, known for fighting disease and epidemics around the globe, to assist local health agencies struggling to keep up with a fast-moving outbreak. The Seattle area has emerged as an epicenter of the new disease, with far more cases and deaths than any other U.S. city.

One of the most important things from our perspective, having watched and worked on this in other parts of the world, is the identification of people who are positive for the virus, so they can be safely isolated and cared for, and the identification of their contacts, who can then be quarantined, Dowell said.

But testing has been limited until now, leaving many people frustrated and frightened. Last week, a laboratory at UW Medicine got approval to begin processing specimens collected by physicians and other health care providers. The Gates-funded project will reduce the need for sick people to visit a doctors office or clinic, lowering the chance of exposing others.

The initiative grew out of the Seattle Flu Study, a 2-year-old research project based at the University of Washington to track the spread of infectious diseases like influenza. Funded with $20 million from Bill Gates private office, the project recruited thousands of volunteers and sent them self-test kits. The focus has now shifted entirely to the new coronavirus, using similar methods to aid the public-health response.

When the expanded testing system is up and running, people in the Seattle area who think they might be infected with SARS-CoV-2, the scientific name for the new coronavirus, can fill out a questionnaire online. If their symptoms are consistent, they can request a test kit, which will be delivered to their home within two hours. The swabs will be collected and delivered to the UW lab.

The Gates Foundation recently announced its committing $5 million for coronavirus response in the Seattle area, and much of that will go for the expanded testing and analysis. While the initial focus will be on the Seattle area, the plan is to eventually expand statewide, Dowell said.

Outside of King County, one person has died and more than 30 infections have been confirmed as of Saturday.

A major goal of the project is to collect as much information as possible online, which will ease the burden on health officials who are stretched thin and hard-pressed to investigate every new case. Local resources have been focused on Life Care Center, the Kirkland nursing home that accounts for the majority of deaths.

They simply dont have enough epidemiologists to do the shoe-leather epidemiology, the house-to-house case identification, Dowell said.

The Seattle Flu Study already has contributed greatly to the understanding of COVID-19, the respiratory disease caused by the new coronavirus. As the outbreak started in China, the scientific team, co-led by Dr. Helen Chu, an infectious-disease specialist at UW Medicine, quickly developed a genetic test for the virus, similar to one they used for flu.

A physician who knew about the work sent in a sample from a teenage patient suspected of having the disease, and the lab was able to identify what was only the second case in the state at that time.

The flu-project scientists also did the first genetic analyses of new coronavirus cases in Washington, and will continue that work. Bedford, the computational biologist, used those first genomes to analyze changes in the virus over time and concluded that it had probably started circulating in the state earlierthan anyone realized.

The Seattle Flu Study has also already been collecting nasal swabs from volunteers for a research study on the new coronavirus. People can still sign up for that study, but they cannot get their individual results yet.

The Seattle Flu Study is led by the Brotman Baty Institute in collaboration with UW Medicine, Fred Hutch and Seattle Childrens hospital.

The Gates Foundation has also committed $100 million to the global coronavirus response, with an emphasis on vaccine and drug development and improved testing, treatment and control in vulnerable parts of Africa and South Asia.

Read the original post:
Gates-funded program will soon offer home-testing kits for new coronavirus - Seattle Times

Read More...

What you need to know about coronavirus testing in the U.S. – Science News

March 8th, 2020 10:44 am

U.S. government officials say a million promised tests for diagnosing coronavirus infections will soon be in the mail. But that still leaves many state and local laboratories without the ability to test for the virus, crucial for curbing its spread around the country.

Some states have developed their owntests. Clinical testing companies are now joining the ranks. LabCorpannounced March 5 that physicians or other authorized health careproviders could already order its test. QuestDiagnostics announced the same day that the company will also offercommercial tests as soon as March 9, pending U.S. Food and Drug Administrationreviews. Participation of those two commercial laboratories could greatlyexpand testing capacity in the United States.

Headlines and summaries of the latest Science News articles, delivered to your inbox

But for now, we still find ourselves asa country with pretty limited capacity to test, says Michael Mina, anepidemiologist at the Harvard T.H. Chan School of Public Health in Boston.

Heres what you need to know aboutcoronavirus testing in the country.

As of March 6, at least 45 states arenow doing testing for SARS-CoV-2, the virus that causes the disease. Wyoming,Oklahoma, Ohio, West Virginia and Maine as well as Guam, Puerto Rico and theVirgin Islands are listed as in progress of having labs certified to dotesting, according to the U.S. Centers for Disease Control and Prevention. Evenstates that have tests may have only a single kit, containing enough materialto test just 700 people, Mina says.

As of March 5, 1,583 people had beentested at CDC. That figure doesnt include tests now going on in many state orcommercial laboratories, which began this week. Contrast that with the UnitedKingdom, where 20,388 people have been tested as of March 6. Only 163 cases ofCOVID-19 have been detected there. Switzerland, which had 181 cases and onedeath as of March 6, has tested more than 3,500 people.

In the United States, more than 250people in at least 23 states had confirmed cases of the coronavirus diseaseknown as COVID-19, and 14 had died, as of March 6. More cases can be expectedas testing ramps up, experts say.

As more cases are found, healthofficials will need to test contacts of people who carry the virus, and otherill people in affected communities may demand tests, all escalating the needfor more tests.

Vice President Mike Pence told reporters March 5, We dont have enough tests today to meet what we anticipate will be the demand going forward, according to CNN. But having companies tests in the mix could help testing ramp up relatively quickly.

To get a more complete picture of howwidespread the virus is in the United States, were going to needmillions and millions and millions of tests, said Anthony Fauci, directorof the National Institute of Allergy and Infectious Diseases in Bethesda, Md.,during a CNN town hall on March 5.

Health professionals will swab apersons nose or throat, collect phlegm coughed up from the lungs, or squirtliquid into the nose, throat or lungs and collect the liquid again for testing.Neither Quest nor LabCorp will collect such specimens, but doctors or otherhealth providers may send samples to the labs for testing.

Then, those samples are analyzed in a laboratory, where technicians must extract and purify the viruss genetic material from the mucus, cell debris and other stuff in the samples.That sample preparation process is usually the biggest bottleneck [in testing], says Brent C. Satterfield, founder and chief scientific officer of Co-Diagnostics, a company based in Salt Lake City and Gujarat, India, that has developed its own coronavirus test. That test can be used clinically in Europe, but has not yet been approved for use in the United States, although other labs can use components of the companys test to build their own diagnostic tests.

All of the coronavirus tests being usedby public health agencies and private labs around the world start with atechnique called polymerase chain reaction, or PCR, which can detect tinyamounts of a viruss genetic material. SARS-CoV-2, the virus that causesCOVID-19, has RNA as its genetic material. That RNA must first be copied intoDNA. Thats a lengthy part of the process, too, says Satterfield, adding 15to 30 minutes to the test.

After that, the PCR can begin. Theprocess makes millions to billions of copies of selected segments of DNA. Inthe case of the coronavirus, the CDCs original test scanned for three of theviruss genes, but now tests for two. The World Health Organizations test,developed by infectious disease researcher Christian Drosten at the Charit UniversittsmedizinBerlin and colleagues, tests for three genes but is a bit different than theCDC tests. The PCR step typically takes 45 minutes to an hour, Satterfieldsays.

Some assays give instant yes or noreadings, but others may also take time to analyze. All together, it may takeabout three hours to complete a test, Satterfield estimates.

PCR tests are not simple enough to do ina doctors office.

In the United States, a doctor is nowallowed to decide if a test is warranted and collect the sample, but then mustship the sample off for other trained professionals to prepare and test.

Testing was initially limited to onlythose people with symptoms and a travel history to an affected area or contactwith a known case. On March 4, the CDCrelaxed some restrictions on who can get tested. People still haveto be sufficiently sick and have failed a flu test in order to qualify forcoronavirus testing, Mina says.

In some states, the positive test results arecalled presumptive positives until the CDC can confirm them. In those cases,the final official result may take days. LabCorp estimates that it will takethree to four days to return results to physicians.

Many doctors offices can do a rapid influenzatest. But those flu tests dont use PCR, Satterfield says. Instead, they detectproteins on the surface of the influenza virus. While the test is quick andcheap, its also not nearly as sensitive as PCR in picking up infections,especially early on before the virus has a chance to replicate, he says. By theCDCs estimates, rapid influenza tests may miss 50 percent to 70 percent ofcases that PCR can detect. The low sensitivity can lead to many false negativetest results.

Flu tests also arent as specific for aparticular virus strain as PCR is. About 5 percent to 10 percent of the time,flu tests may mistake a different virus for the flu, creating a false positiveresult. Specificity is a big deal when youre testing large numbers of peoplewho arent expected to be positive, Satterfield says. If youre going to testin one of the states that doesnt have a coronavirus outbreak right now, with aspecificity of 90 percent, 10 out of every 100 people are going to show uppositive even though the coronavirus isnt there yet.

Accurate diagnosis is a very highimperative for this [coronavirus], Satterfield says.

An additional benefit of a PCR test isthat it may be able to detect viruses earlier in an infection than a flu-style testcan, he says, perhaps not in the first day, but a couple of days into aninfection when the virus is replicating strongly, but the bodys immune systemhasnt yet begun to fight and produce symptoms. In every infectious disease Iknow of, that is the most contagious period for a person; the point in timewhen the virus has multiplied to its maximum capacity and the body has not yetstarted to rein in on it, Satterfield says. Being able to identify people inthat period and isolate them from others could help curb the spread of thedisease.

Delays started with a manufacturing flawin the CDCs original PCR test, which caused components that detect one of the threetargeted viral genes to not work properly, the health agency says.

Those woes sound like user error to Co-DiagnosticsSatterfield. A lot of what they are seeing is probably due to inconsistent usein the field, he says. Tests that work phenomenally well in the lab, whenthey are sent to the field, sometimes just dont work the same, he says.

Co-Diagnostics test also uses PCR buttests for only one gene versus three. Sometimes the more complexity you havein a test, the more things you have that can go wrong, Satterfield says.

Some delays in getting testing off theground came from emergency measures enacted by the FDA, Satterfield says. Normally,big medical testing labs, such as state health labs and companies like LabCorpand Quest Diagnostics, are allowed to develop and validate their own tests. Butwhen the coronavirus was declareda public health emergency on January 31, labs needed emergencyuse authorization before using their tests to diagnose cases. Eventhe CDC had to get permission to use its test. But on February 29, FDAannounced that labs could devise their own tests and use them clinically whilewaiting for the agency to review their applications. FDA does not intend toobject to the use of these tests for clinical testing while the laboratoriesare pursuing an EUA, the agency saidin a statement.

It looks like there were some prettylarge blunders that led to some serious delays, says Mina, the epidemiologistat Harvard. Instead of reducing the amount of testing at the start of anepidemic we should have been expanding it as quickly as possible and callingfor all hands on deck, he says.

Those delays and the initial limitationson who could be tested may have allowed some cases to slip through the cracksand start community outbreaks in Washington and California.

It will vary from place to place. If you have symptoms of COVID-19 fever, dry cough and often fatigue contact your doctor or local or state health department for more information. Do not go to the emergency room for testing, officials say.

The reliable science journalism you count on is expensive. It takes professional reporters, editors, fact checkers, designers and digital producers to make sureScience Newsreflects the depth and breadth of science.We need your financial support to make it happen every contribution makes a difference.

Continue reading here:
What you need to know about coronavirus testing in the U.S. - Science News

Read More...

How to succeed through assisted reproduction? – The New Indian Express

March 8th, 2020 10:44 am

By Express News Service

Assisted reproductive technology (ART) is a rapidly advancing field. Most of the women seeking help regarding infertility issues are aware of the several treatment options available. How can we improve the success in ART?

Several new methods have been introduced to enhance the success rates. Reproductive ability of women decreases as their age advances. This is mainly due to decrease in oocyte quality and quantity. As the quality of oocytes decreases, rate of abnormal chromosomal patterns will increase. Mitochondria plays an important role in egg maturation process. Mitochondrial injection from donor eggs can be injected or those from own precursor cells of the eggs can be injected. This can improve the embryo development.

Egg quality can be improved by adding oral medication to the injectables and also giving double trigger for egg maturation helps at times. For few patients, whose response to medication is not satisfactory (termed poor responders), starting treatment with DHEA (dehydroepiandrosterone) or testosterone gel prior to the in vitro fertilisation (IVF) programme can improve success. Time lapse imaging of embryo enables evaluation of early embryo development, so selection of good embryos can be performed for replacement.

Pre implantation genetic screening to select embryos with high chance of implanting and also to reduce the risk for chromosomal problems. Next comes the lining of the womb. We can look at endometrial wave pattern and implant the embryos. Injecting granulocyte stimulating factor or platelet rich plasma prior to implanting the embryos can help at times. Endometrial Receptivity Analysis (ERA), is a genetic testing method in which we take a small sample of a womans endometrial lining to determine which day would be the best day to transfer the embryos during IVF cycle. It is extremely useful in people who had two or more unsuccessful IVF cycles. The sample taken will be analyzed to assess endometrial receptivity and the optimal day for the transfer.

Ultimately when you are being prepared for IVF programme, quit smoking and alcohol, take prenatal vitamins and get vaccinated against rubella and chicken pox if not already immune. Healthy eating is mandatory. Avoid red meat, refined sugar and processed food. Moderate exercise is acceptable and low impact exercises will really help. Reduce your stress levels and improve your sleep. It is a tedious journey. Yes but, motherhood is every womans right.

Dr Sumana Manohar, MB, FRCOG (LON)Senior Consultant - Obstetrics and Gynaecology Sub-Specialty- Reproductive Medicine, Endoscopy and High Risk Obstetrics Apollo Womens Hospitals Shafee Mohammed Road Thousand Lights, Chennai 6

ERA Endometrial Receptivity Analysis (ERA), is a genetic testing method in which a small sample of a womans endometrial lining is taken to determine which day would be the best to transfer the embryos

Read more from the original source:
How to succeed through assisted reproduction? - The New Indian Express

Read More...

Beating heart cells catch a ride to the International Space Station – The Albany Herald

March 8th, 2020 10:43 am

Tiny heart cells are among the new batch of science experiments heading for the International Space Station Friday night, but their potential to help patients with heart disease on Earth is exponential.

SpaceX's 20th resupply mission to the station is expected to launch Friday night at 11:50 p.m. ET from Cape Canaveral Air Force Station in Florida. It includes supplies, a variety experiments and materials for ongoing research investigations. The Dragon spacecraft will also bring the European Space Agency's Bartolomeo, a commercial research platform that will be installed outside the station, according to NASA.

And nestled among the payloads are two different experiments involving cariomyocytes, or beating heart cells, grown from pluripotent stem cells. Pluripotent stem cells are ideal because they can turned in multiple cell types. In this case, they could become healthy heart cells for a patient with heart disease.

The results of the experiments could be used to generate a multitude of healthy heart cells for children and adults with various heart diseases. But they could also be used to understand heart health and the aging process in a broader context. The researchers for one of the experiments believe their study could even help astronauts with the known risks they experience during long-term spaceflight, like reduced heart function and irregular heartbeat.

"Scientists already know that humans exposed to space experience changes similar to accelerated aging, so we hope the results can help us better understand and someday counteract the aging process," said Deok-Ho Kim, principal investigator for one of the experiments, and associate professor of biomedical engineering and medicine at Johns Hopkins University.

For the next month, the heart cells will undergo a unique journey to space before splashing back down in the Pacific Ocean. Here's what researchers hope to learn about the effects of zero gravity on human heart cells.

Without gravity, cells grow

Emory University School of Medicine associate professor of pediatrics Chunhui Xu first discovered that stem cells grow faster in space by simulating the lack of gravity on Earth. She studies cardiomyocytes with the hopes of improving the heart's regenerative abilities, as well as improving congenital heart disorder treatment.

Stem cell therapies to repair damaged heart cells require at least one billion cells for each patient, Xu said. But they can take time to grow on Earth. When her experiment using simulated microgravity on Earth showed promising steps toward quickly and safely producing cardiomyocytes, Xu saw space as the ultimate proving ground.

Her experiment was chosen to fly on the space station and now she and her team hope they can confirm their ground-based observation and discover new insights as well.

She and her colleagues at Emory had to learn how to cryopreserve the cells so that they can survive the launch and trip to the space station. It also means that the astronauts can unpack everything and organize their experiment schedule, without having to jump right into the experiment for fear of the cells dying.

Once the cells are thawed, the cell cultures will grow for 21 days in the Multi-use Variable-gravity Platform experiment modules built by Techshot, Inc. Then, in an ambitious goal, the cells will actually be returned live, jettisoned in a payload that will land in the Pacific Ocean. A colleague in California will then prep them and have the live cells shipped back to Emory in Atlanta so the researchers can analyze them.

Meanwhile, during the experiment in space, a control group of cells will be put in a centrifuge in a modified gravity environment on Earth.

"We've worked together for years to bring basic and clinical science together," said Dr. Kevin Maher, director of the cardiac intensive care unit at Children's Healthcare of Atlanta Heart Center and professor of pediatrics at Emory University. Maher is working with Xu on the experiment.

There's a high demand on the cells themselves -- they need to be pure and high quality. Residual stem cells that don't turn into heart cells can cause tumors, according to previous research by Xu. More mature cells stand a better chance of becoming pure heart cells. During her ground-based experiment simulating a lack of gravity, Xu found that the cells were more mature and even expressed survival genes that could ensure cell survival. Overall, these factors would allow the cells to connect with the heart tissue better and cause less issues, Xu said.

The implications of their research could help develop a more efficient and cost-effective way to develop the heart cells on Earth for patients in need. Given that heart disease is the leading cause of death in the US, according to the CDC, the cells have great potential to treat children and adults. And the cells could also be used to test new therapies and speed up the development of safe drugs, Xu said.

'Tissue on a chip'

The National Center for Advancing Translational Sciences is continuing its Tissue Chips in Space initiative by funding an experiment that includes a cellphone-sized chip loaded with beating heart tissue.

It starts with a similar base as the Emory experiment: pluripotent stem cells grown into cardiomyocytes. Instead of cell cultures, these are bioengineered mini tissue chips that mimic human heart function.

This allows the cells to signal and act as they would in the body, hosted on a scaffold-like bio-structure holding the tissues together. This encourages the cells inside to grow, and ultimately, this kind of structure could be used to test drugs.

"We hope that this project will give us meaningful data that we can use to understand the heart's structure and how it functions, so that we can improve the health of both astronauts and those down here on Earth," said Kim.

The Johns Hopkins University researchers and their collaborating colleagues at other universities will get measurements of the tissues beating in real time. And after a month, the tissues will return to Earth. The team wants to analyze them and determine how they were affected by microgravity or if their gene expression changed. Heart tissues on Earth, identical to the ones sent to the station, will serve as a control at the University of Washington.

Some of the tissues sent to space will continue to be cultured on Earth for a week afterward in case any recovery efforts can be observed.

"The entire team is excited to see the results we get from this experiment. If successful, we will embark on the second phase of the study where tissues will be sent up to the ISS once again in two years, but this time, we will be able to test a variety of drugs to see which ones will best ameliorate the potentially harmful effects of microgravity on cardiac function," said Jonathan Tsui, a member of Kim's lab and a postdoctoral fellow at Johns Hopkins University's department of biomedical engineering.

View original post here:
Beating heart cells catch a ride to the International Space Station - The Albany Herald

Read More...

Federal government investing nearly $7 million in stem cell research – inthehammer.com

March 8th, 2020 10:43 am

The federal government recently announced their intention to invest $6.9 million in stemcellresearch.

Stem cells are the building blocks of the body, and are responsible for growing and repairing tissue; they have the potential to treat myriad illnesses including heart disease--the leading cause of death inNorthAmerica.

Canada has been one of the leading countries when it comes to stem cell research, and Canadian researchers have brought stem cells from the lab into hospitals to savecountlesslives.

This funding will go towards nine translational projects and four clinical trials across the country aimed at providing new therapies and fostering continued growth in Canada's regenerativemedicinesector.

Two of the projects are being conducted by the Maisonneuve-Rosemont Hospital in Quebec; one trial involves testing a promising new protocol to make blood stem cell transplants available to more patients with severe leukemia, the other is a biotechnology partnership that is advancing a stem cell-based approach tovisionloss.

"When we invest in science, we invest in better, healthier lives for everyone," Navdeep Bains, Minister of Innovation, Science, and Industry, said in anewsrelease.

"Our government's support will help Canadian researchers further their ground-breaking work to tackle some of the most serious illnesses we face today. Congratulations to all of the recipients, and thank you for your work to keep Canada on the cutting edge of discovery and innovation,"hecontinued.

Read more:
Federal government investing nearly $7 million in stem cell research - inthehammer.com

Read More...

‘His legacy lives on’: Grandmother who helped create newborn screening law tells history of bill – News-Leader

March 8th, 2020 10:43 am

Buy Photo

Two-year-old Regann Moore lights up as she watches videos on her iPad at home on Thursday, Feb. 20, 2020. Moore has a rare disease known as Krabbe Disease and received a life-saving stem cell donation less than a month after being born.(Photo: Nathan Papes/Springfield News-Leader)

Soon after the News-Leader published a story about 2-year-old Regann Moore,a Springfield child whose life was saved thanks to a newborn screening test, someone tweeted the story toMissouri State Rep. Becky Ruth.

"I bawled my eyes out," Ruth said. "I just cried."

She cried because she knew Regann is alive thanks to the death of Ruth's grandson, Brady.

"I cry and smile when I see these children," Ruth said. "We are always so thankful. For us, we see Brady's death wasn't in vain. His legacy lives on by helping save the lives of other children."

More: Springfield child with rare, deadly disease continues to amaze doctors, family

Regann, who is 2 now, was diagnosed right after she was born withKrabbe Disease, a rare metabolic disorder that must be diagnosed at birth and treated as soon as possible with a stem cell donation.

The newborn screening is important because babies with Krabbe Disease appear healthy at birth. Signs something is wrong usually don't appear until it's too late for treatment to be effective.

That is what happened to Brady in 2009. He wasn't diagnosed with the disease until he was 4.5 months old too late for treatment.

Brady died 10 days before his first birthday.

Brady Cunningham died of Krabbe Disease just before his first birthday.(Photo: Courtesy of the Cunningham family)

That's why Ruth and her family fought to get lawmakers on board with making sure all newborns in Missouri are screened for Krabbe Disease.

TheBrady Alan Cunningham Newborn Screening Act was passed in 2009 and screening began in 2012. Ruthsaid her family was OK with the three-year lag because they realized the lab needed time to become equipped to test for the disease.

Missouri is one of just a few states that do the newborn screening.

Brady's law also includes screening for Pompe, Fabry, Gauche and Niemann-Pick diseases. Since then, SCID, MPS I, MPS II and SMA diseases are screened, as well.

Ruth became a state representative in 2015and said newborn screening is her passion.

Her experience with getting Brady's law passed is what led her to seek office.

"It showed me what just a regular everyday person can do and what a differenceyou can make," Ruth said. "People a lot of times complain about politicians and the legislature, but we also do very good things here."

Ruth said her family knows of another child with Krabbe Disease who was saved thanks to newborn screening and a stem cell transplant.

That child is now 4. Ruth said her family and that child's family have a "strong connection."Ruth said shehopes to someday meet Regann's family.

Brady Cunningham was born in 2008. His family is from Campbell in southeast Missouri.

Bradyappeared healthy at birth and was not tested for Krabbe Disease.

Ruth said he started having health problems after about a month and a half. Brady went through "a myriad of diagnoses," Ruth recalled, including acid reflux and seizures.

"Finally my daughter took him to Children's Hospital in St. Louis," she said. "They promised her he wouldn't leave without a diagnosis."

Missouri State Rep. Becky Ruth was moved to tears after reading about Regann Moore, a Springfield child whose life was saved thanks to newborn screening for Krabbe Disease. Ruth and her family encouraged Missouri lawmakers to make sure all Missouri babies are tested for the deadly disease after her grandson, Brady, died from it.(Photo: Submitted by Becky Ruth)

Three weeks later, Brady was diagnosed with Krabbe Disease, which rapidly destroys the nervous system.

"We were told there was nothing they could do," she said. "It was one of the worst days of all of our lives."

Brady was 4.5 months old when he was diagnosed. In order for a stem cell donation to have any chance of being effective, babies must have the transplant within the first month of their life.

Regann, the Springfield child, was given a stem cell donation thanks to an umbilical cord donation.

Thediseaseaffects about one in every 100,000 people in the United States.

"They are missing an enzyme that helps keep their nervous system intact," said Dr. Shalini Shenoy, Regann's transplant doctor. "Because this is missing, they have degeneration of the brain and nervous system. And if you let it progress, it is fatal very early."

Without the stem cell donation, babies die within the first few months, Shenoy said.

"You can't change someone's genetic makeup," Shenoy said. "But when you put stem cells into their bone marrow from somebody else who is normal, some of these cells migrate into their brain and into their nervous system and supply what they are lacking themselves."

It takes some time for the transplant to begin working for the transplanted cells to "settle down" and begin making the missing enzyme, Shenoy said.

"Because of that, the earlier you transplant a Krabbe patient, the more you will be able to rescue them," she said. "You want to catch them before too much damage is done. Once there's a lot of nerve damage, it's not reversible. If I saw a Krabbe patient two months after they were born or four months after they were born when they already had major problems, it's unlikely I'd be able to rescue them too much."

Since the screening and the stem cell transplant treatment are both relatively recent medical advancements, Shenoy said it's anybody's guess what the future will hold for children who, like Regann, were successfully treated with a stem cell transplant early on.

Ferrell Moore holds his two-year-old daughter Regann Moore at their home on Thursday, Feb. 20, 2020. Regann has a rare disease known as Krabbe Disease and received a life-saving stem cell donation less than a month after being born.(Photo: Nathan Papes/Springfield News-Leader)

Regann can't stand on her own or walk yet. But her family is determined to make that happen. She cannot talk but is learning sign language to communicate.

She has regular visits with speech and occupational therapists.

Regann's dad Ferrell Moore got to take her to the circus recently, something the little girl seemed to enjoy.

"She is the joy of my life," Ferrell Moore said. "When I come home, it couldn't be any better to see her and how happy she is to see me."

Read or Share this story: https://www.news-leader.com/story/news/local/ozarks/2020/03/05/grandma-who-helped-pass-newborn-screening-law-tells-story-bill/4954655002/

See the rest here:
'His legacy lives on': Grandmother who helped create newborn screening law tells history of bill - News-Leader

Read More...

SpaceX Dragon to launch heart cell experiment and more to space station tonight – Space.com

March 8th, 2020 10:43 am

CAPE CANAVERAL, Fla. SpaceX is preparing for its fifth launch of the year: a resupply mission to the International Space Station (ISS). The mission, which is scheduled to launch Friday (March 6) at 11:50 p.m. EST (0450 GMT on March 7), will bring a bevy of science material to the astronauts living and working in the orbiting laboratory.

This flight, dubbed CRS-20, marks the 20th and final mission for SpaceX under the company's first commercial cargo resupply services contract with NASA. Perched atop a Falcon 9 rocket will sit a cargo Dragon capsule filled with more than 4,300 lbs. (1,950 kilograms) of supplies, including more than 2,100 lbs. (950 kg) of science equipment.

The scientific cargo will support a host of experiments across Expeditions 62 and 63, focusing on a range of topics, from biological sciences (growing human heart cells in space), to water conservation methods, to particle-foam manufacturing and the addition of a new research platform on the ISS.

You can watch SpaceX's Dragon launch livehere on Space.com, courtesy of SpaceX, beginning at about 11:30 p.m. EST (0430 GMT), courtesy of NASA TV. You can alsowatch the launch directly from SpaceX here, beginning at 11:35 p.m. EST (0435 GMT).

Video: What's flying to the space station on SpaceX's CRS-20 mission?Related: SpaceX Dragon cargo ship launching tonight. How to watch live.

In its never-ending quest to create the best athletic shoe, Adidas has turned its sights to the International Space Station. The sportswear company has developed a performance midsole an additional shoe layer between the insole (next to your feet) and the sole (what touches the ground) that will enhance comfort.

To create its midsole, Adidas uses a process called particle foam molding, in which thousands of small pellets are blasted into a mold so they fuse together. To streamline the process and create the best shoe it can, Adidas is going to try this process in microgravity. The experiment, dubbed Adidas BOOST (Boost Orbital Operations on Spheroid Tessellation), will look at how the particles fuse together in space.

By removing gravity from the process, the team can take a closer look at individual pellet motion and location. The results of this investigation could show that the space station is a good platform for testing out new manufacturing methods and could lead to more-efficient means of packing and cushioning materials.

Related: Adidas launching new sneakers inspired by historic NASA spacesuits

Delta Faucet Co., a manufacturer of shower heads and other bathroom hardware, is launching a payload on CRS-20 that will seek to better understand how water droplets form. The company will use that knowledge to build a better shower head that lines up with Delta's ultimate goal: creating the sensation of increased pressure while using less water.

Conserving water is incredibly important, but one of the biggest drawbacks is that eco-friendly, low-flow shower heads do not perform as well as their less environmentally friendly counterparts. Users complain that the water pressure feels so low it's difficult to rinse off properly, which can result in longer showers and, ultimately, more water usage.

To help mitigate this issue, Delta has created a unique shower head, called the H2Okinetic, that controls the size and the speed of the water droplets with the help of an oscillating chip. That chip creates a better shower experience by breaking up the water flow into bigger droplets and shooting them out faster, giving the illusion of more water.

Related: Showering in space: Astronaut home video shows off 'hygiene corner'

"Water is a precious commodity," Garry Marty, principal engineer at Delta Faucet, said during a prelaunch briefing on Thursday (March 5). "We are trying to create a shower head to keep our customers happy while using less water."

He went on to explain that once the water leaves the pipes, it essentially doesn't have any pressure. What you're feeling are the droplets. With this new shower head, Delta Faucet is able to control the size and speed on each drop, revolutionizing the way a shower device delivers a shower.

"Lower-flow showers aren't really great to be under," Marty said. "But the more we understand, the more we can improve."

Marty added that, someday, humanity will be living on the moon or Mars and will need a way to take a shower. The lessons learned from this research go beyond conserving water and user experience, he said; it has implications for the space industry as well. But for now, the bigger concern is to better understand the fundamentals of water droplet formation.

Heart disease is the No. 1 cause of death in the U.S. A team of researchers from Emory University in Atlanta, led by Chunhui Xu, are sending an experiment up to the space station to explore how effectively stem cells can be turned into heart muscle cells.

The data collected could lead to new therapies and even speed up the development of new drugs that can better treat heart disease.

The microgravity environment found on the space station is known to have a profound effect on cell growth. Through this research, the team aims to understand the impact microgravity has on cardiac precursors (cardiac cells created from stem cells) and how effectively they produce cardiac muscle cells, called cardiomyocytes.

Related: Heart cells beat differently in microgravity, may benefit astronauts

Ground-based research shows that when cells are grown under simulated microgravity conditions, the production rate of cardiomyocytes is greater than if they were grown under the effects of gravity. By sending the experiment to the space station, Xu and her team will be able to determine if their results are accurate.

"Our goal is to help make stem cell-based therapy more readily available," Xu said during the briefing. "If successful, the demand for it will be tremendous, because heart disease is the No. 1 killer in America."

In order to have a successful therapy, Xu said that the team will need to produce a large number of high-quality cardiomyocytes. To do that, the researchers need to first understand the mechanisms behind cell transformation.

Bartolomeo is a new research platform that will be installed on the exterior of the space station. Placed outside the European Columbus module, this science balcony will host as many as 12 research experiments at one time.

Built by Airbus, the platform will enable researchers to conduct more experiments on the station's exterior. During a prelaunch briefing, NASA and Airbus explained that Bartolomeos potential uses include Earth observation, robotics, materials science and astrophysics.

"All of your [research] dreams can come true with Bartolomeo," said Andreas Schuette, program manager of Bartolomeo at Airbus.

And parking spots on the washing machine-sized platform are all-inclusive, which means that researchers can pay one price to launch, install, operate and even return to Earth. By working directly with agencies like NASA, ESA, and SpaceX, Airbus is able to offer a cost-effective means of conducting research on the space station.

The company is also working with the United Nations in an effort to entice those who wouldn't otherwise be able to afford to send payloads into space, Schuette told Space.com. The duo have teamed up with the United Nations Office for Outer Space (UNOOSA) to make that happen. (The agency works to make space more accessible.)

If all goes as scheduled, the Dragon will arrive at the International Space Station on Monday (March 9) at approximately 6 a.m. EDT (1000 GMT). From there, NASA astronauts Jessica Meir and Drew Morgan will use the station's Canadarm2 robotic arm to capture and attach the spacecraft, before beginning the unloading process.

Follow Amy Thompson on Twitter @astrogingersnap. Follow us on Twitter @Spacedotcom or Facebook.

Read more:
SpaceX Dragon to launch heart cell experiment and more to space station tonight - Space.com

Read More...

Biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation for functional sweat gland regeneration – Science…

March 8th, 2020 10:43 am

Abstract

Mesenchymal stem cells (MSCs) encapsulation by three-dimensionally (3D) printed matrices were believed to provide a biomimetic microenvironment to drive differentiation into tissue-specific progeny, which made them a great therapeutic potential for regenerative medicine. Despite this potential, the underlying mechanisms of controlling cell fate in 3D microenvironments remained relatively unexplored. Here, we bioprinted a sweat gland (SG)like matrix to direct the conversion of MSC into functional SGs and facilitated SGs recovery in mice. By extracellular matrix differential protein expression analysis, we identified that CTHRC1 was a critical biochemical regulator for SG specification. Our findings showed that Hmox1 could respond to the 3D structure activation and also be involved in MSC differentiation. Using inhibition and activation assay, CTHRC1 and Hmox1 synergistically boosted SG gene expression profile. Together, these findings indicated that biochemical and structural cues served as two critical impacts of 3D-printed matrix on MSC fate decision into the glandular lineage and functional SG recovery.

Mesenchymal stem cells (MSCs) hold great promise for therapeutic tissue engineering and regenerative medicine, largely because of their capacity for self-renewal and multipotent properties (1). However, their uncertain fate has a major impact on their envisioned therapeutic use. Cell fate regulation requires specific transcription programs in response to environmental cues (2, 3). Once stem cells are removed from their microenvironment, their response to environmental cues, phenotype, and functionality could often be altered (4, 5). In contrast to growing information concerning transcriptional regulation, guidance from the extracellular matrix (ECM) governing MSC identity and fate determination is not well understood. It remains an active area of investigation and may provide previously unidentified avenues for MSC-based therapy.

Over the past decade, engineering three-dimensional (3D) ECM to direct MSC differentiation has demonstrated great potential of MSCs in regenerative medicine (6). 3D ECM has been found to be useful in providing both biochemical and biophysical cues and to stabilize newly formed tissues (7). Culturing cells in 3D ECM radically alters the interfacial interactions with the ECM as compared with 2D ECM, where cells are flattened and may lose their differentiated phenotype (8). However, one limitation of 3D materials as compared to 2D approaches was the lack of spatial control over chemistry with 3D materials. One possible solution to this limitation is 3D bioprinting, which could be used to design the custom scaffolds and tissues (9).

In contrast to traditional engineering techniques, 3D cell printing technology is especially advantageous because it can integrate multiple biophysical and biochemical cues spatially for cellular regulation and ensure complex structures with precise control and high reproducibility. In particular, for our final goal of clinical practice, extrusion-based bioprinting may be more appropriate for translational application. In addition, as a widely used bioink for extrusion bioprinting, alginate-based hydrogel could maintain stemness of MSC due to the bioinert property and improve biological activity and printability by combining gelatin (10).

Sweat glands (SGs) play a vital role in thermal regulation, and absent or malfunctioning SGs in a hot environment can lead to hyperthermia, stroke, and even death in mammals (11, 12). Each SG is a single tube consisting of a functionally distinctive duct and secretory portions. It has low regenerative potential in response to deep dermal injury, which poses a challenge for restitution of lost cells after wound (13). A major obstacle in SG regeneration, similar to the regeneration of most other glandular tissues, is the paucity of viable cells capable of regenerating multiple tissue phenotypes (12). Several reports have described SG regeneration in vitro; however, dynamic morphogenesis was not identified nor was the overall function of the formed tissues explored (1416). Recent advances in bioprinting and tissue engineering led to the complexities in the matrix design and fabrication with appropriate biochemical cues and biophysical guidance for SG regeneration (1719).

Here, we adopted 3D bioprinting technique to mimic the regenerative microenvironment that directed the specific SG differentiation of MSCs and ultimately guided the formation and function of glandular tissue. We used alginate/gelatin hydrogel as bioinks in this present study due to its good cytocompatibility, printability, and structural maintenance in long-time culture. Although the profound effects of ECM on cell differentiation was well recognized, the importance of biochemical and structural cues of 3D-printed matrix that determined the cell fate of MSCs remained unknown; thus, the present study demonstrated the role of 3D-printed matrix cues on cellular behavior and tissue morphogenesis and might help in developing strategies for MSC-based tissue regeneration or directing stem cell lineage specification by 3D bioprinting.

The procedure for printing the 3D MSC-loaded construct incorporating a specific SG ECM (mouse plantar region dermis, PD) was shown schematically in Fig. 1A. A 3D cellular construct with cross section 30 mm 30 mm and height of 3 mm was fabricated by using the optimized process parameter (20). The 3D construct demonstrated a macroporous grid structure with hydrogel fibers evenly distributed according to the computer design. Both the width of the fibers and the gap between the fibers were homogeneous, and MSCs were embedded uniformly in the hydrogel matrix fibers to result in a specific 3D microenvironment. (Fig. 1B).

(A) Schematic description of the approach. (B) Full view of the cellular construct and representative microscopic and fluorescent images and the quantitative parameters of 3D-printed construct (scale bars, 200 m). Photo credit: Bin Yao, Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA. (C) Representative microscopy images of cell aggregates and tissue morphology at 3, 7, and 14 days of culture (scale bars, 50 m) and scanning electron microscopy (sem) images of 3D structure (scale bars, 20 m). PD+/PD, 3D construct with and without PD. (D) DNA contents, collagen, and GAGs of native tissue and PD. (E) Proliferating cells were detected through Ki67 stain at 3, 7, and 14 days of culture. (F) Live/dead assay show cell viability at days 3, 7, and 14. *P < 0.05.

During the maintenance of constructs for stem cell expansion, MSCs proliferated to form aggregates of cells but self-assembled to an SG-like structure only with PD administration (Fig. 1C and fig. S1, A to C). We carried out DNA quantification assay to evaluate the cellular content in PD and found the cellular matrix with up to 90% reduction, only 3.4 0.7 ng of DNA per milligram tissue remaining in the ECM. We also estimated the proportions of collagen and glycosaminoglycans (GAGs) in ECM through hydroxyproline assay and dimethylmethylene blue assay, the collagen contents could increase to 112.6 11.3%, and GAGs were well retained to 81 9.6% (Fig. 1D). Encapsulated cells were viable, with negligible cell death apparent during extrusion and ink gelation by ionic cross-linking, persisting through extended culture in excess of 14 days. The fluorescence intensity of Ki67 of MSCs cultured in 2D condition decreased from days 3 (152.7 13.4) to 14 (29.4 12.9), while maintaining higher intensity of MSCs in 3D construct (such as 211.8 19.4 of PD+3D group and 209.1 22.1 of PD3D group at day 14). And the cell viability in 3D construct was found to be sufficiently high (>80%) when examined on days 3, 7, and 14. The phenomenon of cell aggregate formation and increased cell proliferation implied the excellent cell compatibility of the hydrogel-based construct and promotion of tissue development of 3D architectural guides, which did not depend on the presence or absence of PD (Fig. 1, E and F).

The capability of 3D-printed construct with PD directing MSC to SGs in vitro was investigated. The 3D construct was dissolved, and cells were isolated at days 3, 7, and 14 for transcriptional analysis. Expression of the SG markers K8 and K18 was higher from the 3D construct with (3D/PD+) than without PD (3D/PD); K8 and K18 expression in the 3D/PD construct was similar to with control that MSCs cultured in 2D condition, which implied the key role of PD in SG specification. As compared with the 2D culture condition, 3D administration (PD+) up-regulated SG markers, which indicated that the 3D structure synergistically boosted the MSC differentiation (Fig. 2A).

(A) Transcriptional expression of K8, K18, Fxyd2, Aqp5, and ATP1a1 in 3D-bioprinted cells with and without PD in days 3, 7, and 14 culture by quantitative real-time polymerase chain reaction (qRT-PCR). Data are means SEM. (B) Comparison of SG-specific markers K8 and K18 in 3D-bioprinted cells with and without PD (K8 and K18, red; DAPI, blue; scale bars, 50 m). (C and D) Comparison of SG secretion-related markers ATP1a1 (C) and Ca2+ (D) in 3D-bioprinted cells with and without PD [ATP1a1 and Ca2+, red; 4,6-diamidino-2-phenylindole (DAPI), blue; scale bars, 50 m].

In addition, we tested secretion-related genes to evaluate the function of induced SG cells (iSGCs). Although levels of the ion channel factors of Fxyd2 and ATP1a1 were increased notably in 2D culture with PD and ATP1a1 up-regulated in the 3D/PD construct, all the secretory genes of Fxyd2, ATP1a1, and water transporter Aqp5 showed the highest expression level in the 3D/PD+ construct (Fig. 2A). Considering the remarkable impact, further analysis focused on 3D constructs.

Immunofluorescence staining confirmed the progression of MSC differentiation. At day 7, cells in the 3D/PD+ construct began to express K8 and K18, which was increased at day 14, whereas cells in the 3D/PD construct did not express K8 and K18 all the time (Fig. 2B and fig. S2A). However, the expression of ATP1a1 (ATPase Na+/K+ transporting subunit alpha 1) and free Ca2+ concentration did not differ between cells in the 3D/PD+ and 3D/PD constructs (Fig. 2, C and D). By placing MSCs in such a 3D environment, secretion might be stimulated by rapid cell aggregation without the need for SG lineage differentiation. Cell aggregationimproved secretion might be due to the benefit of cell-cell contact (fig. S2B) (21, 22).

To map the cell fate changes during the differentiation between MSCs and SG cells, we monitored the mRNA levels of epithelial markers such as E-cadherin, occludin, Id2, and Mgat3 and mesenchymal markers N-cadherin, vimentin, Twist1, and Zeb2. The cells transitioned from a mesenchymal status to a typical epithelial-like status accompanied by mesenchymal-epithelial transition (MET), then epithelial-mesenchymal transition (EMT) occurred during the further differentiation of epithelial lineages to SG cells (fig. S3A). In addition, MET-related genes were dynamically regulated during the SG differentiation of MSCs. For example, the mesenchymal markers N-cadherin and vimentin were down-regulated from days 1 to 7, which suggested cells losing their mesenchymal phenotype, then were gradually up-regulated from days 7 to 10 in their response to the SG phenotype and decreased at day 14. The epithelial markers E-cadherin and occludin showed an opposite expression pattern: up-regulated from days 1 to 5, then down-regulated from days 7 to 10 and up-regulated again at day 14. The mesenchymal transcriptional factors ZEB2 and Twist1 and epithelial transcriptional factors Id2 and Mgat3 were also dynamically regulated.

We further analyzed the expression of these genes at the protein level by immunofluorescence staining (figs. S3B and S4). N-cadherin was down-regulated from days 3 to 7 and reestablished at day 14, whereas E-cadherin level was increased from days 3 to 7 and down-regulated at day 14. Together, these results indicated that a sequential and dynamic MET-EMT process underlie the differentiation of MSCs to an SG phenotype, perhaps driving differentiation more efficiently (23). However, the occurrence of the MET-EMT process did not depend on the presence of PD. Thus, a 3D structural factor might also participate in the MSC-specific differentiation (fig. S3C).

To investigate the underlying mechanism of biochemical cues in lineage-specific cell fate, we used quantitative proteomics analysis to screen the ECM factors differentially expressed between PD and dorsal region dermis (DD) because mice had eccrine SGs exclusively present in the pads of their paws, and the trunk skin lacks SGs. In total, quantitative proteomics analyses showed higher expression levels of 291 proteins in PD than DD. Overall, 66 were ECM factors: 23 were significantly up-regulated (>2-fold change in expression). We initially determined the level of proteins with the most significant difference after removing keratins and fibrin: collagen triple helix repeat containing 1 (CTHRC1) and thrombospondin 1 (TSP1) (fig. S5). Western blotting was performed to further confirm the expression level of CTHRC1 and TSP1, and we then confirmed that immunofluorescence staining at different developmental stages in mice revealed increased expression of CTHRC1 in PD with SG development but only slight expression in DD at postnatal day 28, while TSP1 was continuously expressed in DD and PD during development (Fig. 3, A to C). Therefore, TSP1 was required for the lineage-specific function during the differentiation in mice but was not dispensable for SG development.

(A and B) Differential expression of CTHRC1 and TSP1in PD and back dermis (DD) ECM of mice by proteomics analysis (A) and Western blotting (B). (C) CTHRC1 and TSP1 expression in back and plantar skin of mice at different developmental times. (Cthrc1/TSP1, red; DAPI, blue; scale bars, 50 m).

According to previous results of the changes of SG markers, 3D structure and PD were both critical to SG fate. Then, we focused on elucidating the mechanisms that underlie the significant differences observed in 2D and 3D conditions with or without PD treatment. To this end, we performed transcriptomics analysis of MSCs, MSCs treated with PD, MSCs cultured in 3D construct, and MSC cultured in 3D construct with PD after 3-day treatment. We noted that the expression profiles of MSCs treated with 3D, PD, or 3D/PD were distinct from the profiles of MSCs (Fig. 4A). Through Gene Ontology (GO) enrichment analysis of differentially expressed genes, it was shown that PD treatment in 2D condition induced up-regulation of ECM and inflammatory response term, and the top GO term for MSCs in 3D construct was ECM organization and extracellular structure organization. However, for the MSCs with 3D/PD treatment, we found very significant overrepresentation of GO term related to branching morphogenesis of an epithelial tube and morphogenesis of a branching structure, which suggested that 3D structure cues and biochemical cues synergistically initiate the branching of gland lineage (fig S6). Heat maps of differentially expressed ECM organization, cell division, gland morphogenesis, and branch morphogenesis-associated genes were shown in fig. S7. To find the specific genes response to 3D structure cues facilitating MSC reprogramming, we analyzed the differentially expressed genes of four groups of cells (Fig. 4B). The expression of Vwa1, Vsig1, and Hmox1 were only up-regulated with 3D structure stimulation, especially the expression of Hmox1 showed a most significant increase and even showed a higher expression addition with PD, which implied that Hmox1 might be the transcriptional driver of MSC differentiation response to 3D structure cues. Differential expression of several genes was confirmed by quantitative polymerase chain reaction (qPCR): Mmp9, Ptges, and Il10 were up-regulated in all the treated groups. Likewise, genes involving gland morphogenesis and branch morphogenesis such as Bmp2, Tgm2, and Sox9 showed higher expression in 3D/PD-treated group. Bmp2 was up-regulated only in 3D/PD-treated group, combined with the results of GO analysis, we assumed that Bmp2 initiated SG fate through inducing branch morphogenesis and gland differentiation (Fig. 4C).

(A) Gene expression file of four groups of cells (R2DC, MSCs; R2DT, MSC with PD treatment; R3DC, MSC cultured in 3D construct; and R3DT, MSC treated with 3D/PD). (B) Up-regulated genes after treatment (2DC, MSCs; 2DT, MSC with PD treatment; 3DC, MSC cultured in 3D construct; and 3DT, MSC treated with 3D/PD). (C) Differentially expressed genes were further validated by RT-PCR analysis. [For all RT-PCR analyses, gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with 40 cycles, data are represented as the means SEM, and n = 3].

To validate the role of HMOX1 and CTHRC1 in the differentiation of MSCs to SG lineages, we analyzed the gene expression of Bmp2 by regulating the expression of Hmox1 and CTHRC1 based on the 3D/PD-treated MSCs. The effects of caffeic acid phenethyl ester (CAPE) and tin protoporphyrin IX dichloride (Snpp) on the expression of Hmox1 were evaluated by quantitative real-time (qRT)PCR. Hmox1 expression was significantly activated by CAPE and reduced by Snpp. Concentration of CTHRC1 was increased with recombinant CTHRC1 and decreased with CTHRC1 antibody. That is, it was negligible of the effects of activator and inhibitor of Hmox1 and CTHRC1 on cell proliferation (fig. S8, A and B). Hmox1 inhibition or CTHRC1 neutralization could significantly reduce the expression of Bmp2, while Hmox1 activation or increased CTHRC1 both activated Bmp2 expression. Furthermore, Bmp2 showed highest expression by up-regulation of Hmox1 and CTHRC1 simultaneously and sharply decreased with down-regulation of Hmox1 and CTHRC1 at the same time (Fig. 5A). Immunofluorescent staining revealed that the expression of bone morphogenetic protein 2 (BMP2) at the translational level with CTHRC1 and Hmox1 regulation showed a similar trend with transcriptional changes (Fig. 5B). Likewise, the expression of K8 and K18 at transcriptional and translational level changed similarly with CTHRC1 and Hmox1 regulation (fig. S9, A and B). These results suggested that CTHRC1 and Hmox1 played an essential role in SG fate separately, and they synergistically induced SG direction from MSCs (Fig. 5C).

(A and B) Transcriptional analysis (A) and translational analysis (PD, MSCs; PD+, MSCs with 3D/PD treatment; CAPE, MSCs treated with 3D/PD and Hmox1 activator; Snpp, MSCs treated with 3D/PD and Hmox1 inhibitor; Cthrc1, MSCs treated with 3D/PD and recombinant CTHRC1; anti, MSCs treated with 3D/PD and CTHRC1 antibody: +/+, MSCs treated with 3D/PD and Hmox1 activator and recombinant CTHRC1; and /, MSCs treated with 3D/PD and Hmox1 inhibitor and CTHRC1 antibody. Data are represented as the means SEM and n = 3) (B) of bmp2 with regulation of CTHRC1 and Hmox1. (C) The graphic illustration of 3D-bioprinted matrix directed MSC differentiation. CTHRC1 is the main biochemical cues during SG development, and structural cues up-regulated the expression of Hmox1 synergistically initiated branching morphogenesis of SG. *P < 0.05.

Next, we sought to assess the repair capacity of iSGCs for in vivo implications, the 3D-printed construct with green fluorescent protein (GFP)labeled MSCs was transplanted in burned paws of mice (Fig. 6A). We measured the SG repair effects by iodine/starch-based sweat test at day 14. Only mice with 3D/PD treatment showed black dots on foot pads (representing sweating), and the number increased within 10 min; however, no black dots were observed on untreated and single MSC-transplanted mouse foot pads even after 15 min (Fig. 6B). Likewise, hematoxylin and eosin staining analysis revealed SG regeneration in 3D/PD-treated mice (Fig. 6C). GFP-positive cells were characterized as secretory lumen expressing K8, K18, and K19. Of note, the GFP-positive cells were highly distributed in K14-positive myoepithelial cells of SGs but were absent in K14-positive repaired epidermal wounds (Fig. 6, D and E). Thus, differentiated MSCs enabled directed restitution of damaged SG tissues both at the morphological and functional level.

(A) Schematic illustration of approaches for engineering iSGCs and transplantation. (B) Sweat test of mice treated with different cells. Photo credit: Bin Yao, Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Sciences, General Hospital of PLA. (C) Histology of plantar region without treatment and transplantation of MSCs and iSGCs (scale bars, 200 m). (D) Involvement of GFP-labeled iSGCs in directed regeneration of SG tissue in thermal-injured mouse model (K14, red; GFP, green; DAPI, blue; scale bar, 200 m). (E) SG-specific markers K14, K19, K8, and K18 detected in regenerated SG tissue (arrows). (K14, K19, K8, and K18, red; GFP, green; scale bars, 50 m).

A potential gap in MSC-based therapy still exists between current understandings of MSC performance in vivo in their microenvironment and their intractability outside of that microenvironment (24). To regulate MSCs differentiation into the right phenotype, an appropriate microenvironment should be created in a precisely controlled spatial and temporal manner (25). Recent advances in innovative technologies such as bioprinting have enabled the complexities in the matrix design and fabrication of regenerative microenvironments (26). Our findings demonstrated that directed differentiation of MSCs into SGs in a 3D-printed matrix both in vitro and in vivo was feasible. In contrast to conventional tissue-engineering strategies of SG regeneration, the present 3D-printing approach for SG regeneration with overall morphology and function offered a rapid and accurate approach that may represent a ready-to-use therapeutic tool.

Furthermore, bioprinting MSCs successfully repaired the damaged SG in vivo, suggesting that it can improve the regenerative potential of exogenous differentiated MSCs, thereby leading to translational applications. Notably, the GFP-labeled MSC-derived glandular cells were highly distributed in K14-positive myoepithelial cells of newly formed SGs but were absent in K14-positive repaired epidermal wounds. Compared with no black dots were observed on single MSC-transplanted mouse foot pads, the black dots (representing sweating function) can be observed throughout the entire examination period, and the number increased within 10 min on MSC-bioprinted mouse foot pads. Thus, differentiated MSCs by 3D bioprinting enabled exclusive restitution of damaged SG tissues morphologically and functionally.

Although several studies indicated that engineering 3D microenvironments enabled better control of stem cell fates and effective regeneration of functional tissues (2730), there were no studies concerning the establishment of 3D-bioprinted microenvironments that can preferentially induce MSCs differentiating into glandular cells with multiple tissue phenotypes and overall functional tissue. To find an optimal microenvironment for promoting MSC differentiation into specialized progeny, biochemical properties are considered as the first parameter to ensure SG specification. In this study, we used mouse PD as the main composition of a tissue-specific ECM. As expected, this 3D-printed PD+ microenvironment drove the MSC fate decision to enhance the SG phenotypic profile of the differentiated cells. By ECM differential protein expression analysis, we identified that CTHRC1 was a critical biochemical regulator of 3D-printed matrix for SG specification. TSP1 was required for the lineage-specific function during the differentiation in mice but was not dispensable for SG development. Thus, we identified CTHRC1 as a specific factor during SG development. To our knowledge, this is the first demonstration of CTHRC1 involvement in dictating MSC differentiation to SG, highlighting a potential therapeutic tool for SG injury.

The 3D-printed matrix also provided architectural guides for further SG morphogenesis. Our results clearly show that the 3D spatial dimensionality allows for better cell proliferation and aggregation and affect the characteristics of phenotypic marker expression. Notably, the importance of 3D structural cues on MSC differentiation was further proved by MET-EMT process during differentiation, where the influences did not depend on the presence of biochemical cues. To fully elucidate the underlying mechanisms, we first examined how 3D structure regulating stem cell fate choices. According to our data, Hmox1 is highly up-regulated in 3D construct, which were supposed to response to hypoxia, with a previously documented role in MSC differentiation (31, 32). It is suggested that 3D microenvironment induced rapid cell aggregation leading to hypoxia and then activated the expression of Hmox1.

Through regulation of the expression of Hmox1 and addition or of CTHRC1 in the matrix, we confirmed that each of them is critical for SG reprogramming, respectively. Thus, biochemical and structural cues of 3D-printed matrix synergistically creating a microenvironment could enhance the accuracy and efficiency of MSC differentiation, thereby leading to resulting SG formation. Although we further need a more extensive study examining the role of other multiple cues and their possible overlap function in regulating MSC differentiation, our findings suggest that CTHRC1 and Hmox1 provide important signals that cooperatively modulate MSC lineage specification toward sweat glandular lineage. The 3D structure combined with PD stimulated the GO functional item of branch morphogenesis and gland formation, which might be induce by up-regulation of Bmp2 based on the verification of qPCR results. Although our results could not rule out the involvement of other factors and their possible overlapping role in regulating MSC lineage specification toward SGs, our findings together with several literatures suggested that BMP2 plays a critical role in inducing branch morphogenesis and gland formation (3335).

In summary, our findings represented a novel strategy of directing MSC differentiation for functional SG regeneration by using 3D bioprinting and pave the way for a potential therapeutic tool for other complex glandular tissues as well as further investigation into directed differentiation in 3D conditions. Specifically, we showed that biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation, and our results highlighted the importance of 3D-printed matrix cues as regulators of MSC fate decisions. This avenue opens up the intriguing possibility of shifting from genetic to microenvironmental manipulations of cell fate, which would be of particular interest for clinical applications of MSC-based therapies.

The main aim and design of the study was first to determine whether by using 3D-printed microenvironments, MSCs can be directed to differentiate and regenerate SGs both morphologically and functionally. Then, to investigate the underlying molecular mechanism of biochemical and structural cues of 3D-printed matrix involved in MSCs reprogramming. The primary aims of the study design were as follows: (i) cell aggregation and proliferation in a 3D-bioprinted construct; (ii) differentiation of MSCs at the cellular phenotype and functional levels in the 3D-bioprinted construct; (iii) the MET-EMT process during differentiation; (iv) differential protein expression of the SG niche in mice; (v) differential genes expression of MSCs in 3D-bioprinted construct; (vi) the key role of CTHRC1 and HMOX1 in MSCs reprogramming to SGCs; and (vii) functional properties of regenerated SG in vivo.

Gelatin (Sigma-Aldrich, USA) and sodium alginate (Sigma-Aldrich, USA) were dissolved in phosphate-buffered saline (PBS) at 15 and 1% (w/v), respectively. Both solutions were sterilized under 70C for 30 min three times at an interval of 30 min. The sterilized solutions were packed into 50-ml centrifuge tubes, stored at 4C, and incubated at 37C before use.

From wild-type C57/B16 mice (Huafukang Co., Beijing) aged 5 days old, dermal homogenates were prepared by homogenizing freshly collected hairless mouse PD with isotonic phosphate buffer (pH 7.4) for 20 min in an ice bath to obtain 25% (w/v) tissue suspension. The supernatant was obtained after centrifugation at 4C for 20 min at 10,000g. The DNA content was determined using Hoechst 33258 assay (Beyotime, Beijing). The fluorescence intensity was measured to assess the amount of remaining DNA within the decellularized ECMs and the native tissue using a fluorescence spectrophotometer (Thermo Scientific, Evolution 260 Bio, USA). The GAGs content was estimated via 1,9-dimethylmethylene blue solution staining. The absorbance was measured with microplate reader at wavelength of 492 nm. The standard curve was made using chondroitin sulfate A. The total COL (Collagen) content was determined via hydroxyproline assay. The absorbance of the samples was measured at 550 nm and quantified by referring to a standard curve made with hydroxyproline.

MSCs were bioprinted with matrix materials by using an extrusion-based 3D bioprinter (Regenovo Co., Bio-Architect PRO, Hangzhou). Briefly, 10 ml of gelatin solution (10% w/v) and 5 ml of alginate solution (2% w/v) were warmed under 37C for 20 min, gently mixed as bioink and used within 30 min. MSCs were collected from 100-mm dishes, dispersed into single cells, and 200 l of cell suspension was gently mixed with matrix material under room temperature with cell density 1 million ml1. PD (58 g/ml) was then gently mixed with bioink. Petri dishes at 60 mm were used as collecting plates in the 3D bioprinting process. Within a temperature-controlled chamber of the bioprinter, with temperature set within the gelation region of gelatin, the mixture of MSCs and matrix materials was bioprinted into a cylindrical construct layer by layer. The nozzle-insulation temperature and printing chamber temperature were set at 18 and 10C, respectively; nozzles with an inner diameter of 260 m were chosen for printing. The diameter of the cylindrical construct was 30 mm, with six layers in height. After the temperature-controlled bioprinting process, the printed 3D constructs were immersed in 100-mM calcium chloride (Sigma-Aldrich, USA) for 3 min for cross-linking, then washed with Dulbeccos modified Eagle medium (DMEM) (Gibco, USA) medium for three times. The whole printing process was finished in 10 min. The 3D cross-linked construct was cultured in DMEM in an atmosphere of 5% CO2 at 37C. The culture medium was changed to SG medium [contains 50% DMEM (Gibco, New York, NY) and 50% F12 (Gibco) supplemented with 5% fetal calf serum (Gibco), 1 ml/100 ml penicillin-streptomycin solution, 2 ng/ml liothyronine sodium (Gibco), 0.4 g/ml hydrocortisone succinate (Gibco), 10 ng/ml epidermal growth factor (PeproTech, Rocky Hill, NJ), and 1 ml/100 ml insulin-transferrin-selenium (Gibco)] 2 days later. The cell morphology was examined and recorded under an optical microscope (Olympus, CX40, Japan).

Fluorescent live/dead staining was used to determine cell viability in the 3D cell-loaded constructs according to the manufacturers instructions (Sigma-Aldrich, USA). Briefly, samples were gently washed in PBS three times. An amount of 1 M calcein acetoxymethyl (calcein AM) ester (Sigma-Aldrich, USA) and 2 M propidium iodide (Sigma-Aldrich, USA) was used to stain live cells (green) and dead cells (red) for 15 min while avoiding light. A laser scanning confocal microscopy system (Leica, TCSSP8, Germany) was used for image acquisition.

The cell-printed structure was harvested and fixed with a solution of 4% paraformaldehyde. The structure was embedded in optimal cutting temperature (OCT) compound (Sigma-Aldrich, USA) and sectioned 10-mm thick by using a cryotome (Leica, CM1950, Germany). The sliced samples were washed repeatedly with PBS solution to remove OCT compound and then permeabilized with a solution of 0.1% Triton X-100 (Sigma-Aldrich, USA) in PBS for 5 min. To reduce nonspecific background, sections were treated with 0.2% bovine serum albumin (Sigma-Aldrich, USA) solution in PBS for 20 min. To visualize iSGCs, sections were incubated with primary antibody overnight at 4C for anti-K8 (1:300), anti-K14 (1:300), anti-K18 (1:300), anti-K19 (1:300), anti-ATP1a1 (1:300), anti-Ki67 (1:300), antiN-cadherin (1:300), antiE-cadherin (1:300), anti-CTHRC1 (1:300), or anti-TSP1 (1:300; all Abcam, UK) and then incubated with secondary antibody for 2 hours at room temperature: Alexa Fluor 594 goat anti-rabbit (1:300), fluorescein isothiocyanate (FITC) goat anti-rabbit (1:300), FITC goat anti-mouse (1:300), or Alexa Fluor 594 goat anti-mouse (1:300; all Invitrogen, CA). Sections were also stained with 4,6-diamidino-2-phenylindole (Beyotime, Beijing) for 15 min. Stained samples were visualized, and images were captured under a confocal microscope.

To harvest the cells in the construct, the 3D constructs were dissolved by adding 55 mM sodium citrate and 20 mM EDTA (Sigma-Aldrich, USA) in 150 mM sodium chloride (Sigma-Aldrich, USA) for 5 min while gently shaking the petri dish for better dissolving. After transfer to 15-ml centrifuge tubes, the cell suspensions were centrifuged at 200 rpm for 3 min, and the supernatant liquid was removed to harvest cells for further analysis.

Total RNA was isolated from cells by using TRIzol reagent (Invitrogen, USA) following the manufacturers protocol. RNA concentration was measured by using a NanoPhotometer (Implen GmbH, P-330-31, Germany). Reverse transcription involved use of a complementary DNA synthesis kit (Takara, China). Gene expression was analyzed quantitatively by using SYBR green with the 7500 Real-Time PCR System (Takara, China). The primers and probes for genes were designed on the basis of published gene sequences (table S1) (National Center for Biotechnology Information and PubMed). The expression of each gene was normalized to that for glyceraldehyde-3-phosphate dehydrogenase and analyzed by the 2-CT method. Each sample was assessed in triplicate.

The culture medium was changed to SG medium with 2 mM CaCl2 for at least 24 hours, and cells were loaded with fluo-3/AM (Invitrogen, CA) at a final concentration of 5 M for 30 min at room temperature. After three washes with calcium-free PBS, 10 M acetylcholine (Sigma-Aldrich, USA) was added to cells. The change in the Fluo 3 fluorescent signal was recorded under a laser scanning confocal microscopy.

Cell proliferation was evaluated through CCK-8 (Cell counting kit-8) assay. Briefly, cells were seeded in 96-well plates at the appropriate concentration and cultured at 37C in an incubator for 4 hours. When cells were adhered, 10 l of CCK-8 working buffer was added into the 96-well plates and incubated at 37C for 1 hour. Absorbance at 450 nm was measured with a microplate reader (Tecan, SPARK 10M, Austria).

Proteomics of mouse PD and DD involved use of isobaric tags for relative and absolute quantification (iTRAQ) in BGI Company, with differentially expressed proteins detected in PD versus DD. Twofold greater difference in expression was considered significant for further study.

Tissues were grinded and lysed in radioimmunoprecipitation assay buffer (Beyotime, Nanjing). Proteins were separated by 12% SDSpolyacrylamide gel electrophoresis and transferred to a methanol-activated polyvinylidene difluoride membrane (GE Healthcare, USA). The membrane was blocked for 1 hour in PBS with Tween 20 containing 5% bovine serum albumin (Sigma-Aldrich, USA) and probed with the antibodies anti-CTHRC1 (1:1000) and anti-TSP1 (1:1000; both Abcam, UK) overnight at 4C. After 2 hours of incubation with goat anti-rabbit horseradish peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology, CA), the protein bands were detected by using luminal reagent (GE Healthcare, ImageQuant LAS 4000, USA).

Total RNA was prepared with TRIzol (Invitrogen), and RNA sequencing was performed using HiSeq 2500 (Illumina). Genes with false discovery rate < 0.05, fold difference > 2.0, and mean log intensity > 2.0 were considered to be significant.

CAPE or Snpp was gently mixed with bioink at a concentration of 10 M. Physiological concentration of CTHRC1 was measured by enzyme linked immunosorbent assay (ELISA) (80 ng/ml), and then recombinant CTHRC1 or CTHRC1 antibody was added into the bioink at a concentration of 0.4 g/ml. The effect of inhibitor and activator was estimated by qRT-PCR or ELISA.

Mice were anesthetized with pentobarbital (100 mg/kg) and received subcutaneous buprenorphine (0.1 mg/kg) preoperatively. Full-thickness scald injuries were created on paw pads with soldering station (Weller, WSD81, Germany). Mice recovered in clean cages with paper bedding to prevent irritation or infection. Mice were monitored daily and euthanized at 30 days after wounding. Mice were maintained in an Association for Assessment and Accreditation of Laboratory Animal Careaccredited animal facility, and procedures were performed with Institutional Animal Care and Use Committeeapproved protocols.

MSCs in 3D-printed constructs with PD were cultured with DMEM for 2 days and then replaced with SG medium. The SG medium was changed every 2 days, and cells were harvested on day 12. The K18+ iSGCs were sorting through flow cytometry and injected into the paw pads (1 106 cells/50 l) of the mouse burn model by using Microliter syringes (Hamilton, 7655-01, USA). Then, mice were euthanized after 14 days; feet were excised and fixed with 10% formalin (Sigma-Aldrich, USA) overnight for paraffin sections and immunohistological analysis.

The foot pads of anesthetized treated mice were first painted with 2% (w/v) iodine/ethanol solution then with starch/castor oil solution (1 g/ml) (Sigma-Aldrich, USA). After drying, 50 l of 100 M acetylcholine (Sigma-Aldrich, USA) was injected subcutaneously into paws of mice. Pictures of the mouse foot pads were taken after 5, 10, and 15 min.

All data were presented as means SEM. Statistical analyses were performed using GraphPad Prism7 statistical software (GraphPad, USA). Significant differences were calculated by analysis of variance (ANOVA), followed by the Bonferroni test when performing multiple comparisons between groups. P < 0.05 was considered as a statistically significant difference.

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/10/eaaz1094/DC1

Fig. S1. Biocompatibility of 3D-bioprinted construct and cellular morphology in 2D monolayer culture.

Fig. S2. Expression of SG-specific and secretion-related markers in MSCs and SG cells in vitro.

Fig. S3. Transcriptional and translational expression of epithelial and mesenchymal markers in 3D-bioprinted cells with and without PD.

Fig. S4. Expression of N- and E-cadherin in MSCs and SG cells in 2D monolayer culture.

Fig. S5. Proteomic microarray assay of differential gene expression between PD and DD ECM in postnatal mice.

Fig. S6. GO term analysis of differentially expressed pathways.

Fig. S7. Heat maps illustrating differential expression of genes implicated in ECM organization, cell division, and gland and branch morphogenesis.

Fig. S8. The expression of Hmox1 and the concentration of CTHRC1 on treatment and the related effects on cell proliferation.

Fig. S9. The expression of K8 and K18 with Hmox1 and CTHRC1 regulation.

Table S1. Primers for qRT-PCR of all the genes.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Acknowledgments: Funding: This study was supported in part by the National Nature Science Foundation of China (81571909, 81701906, 81830064, and 81721092), the National Key Research Development Plan (2017YFC1103300), Military Logistics Research Key Project (AWS17J005), and Fostering Funds of Chinese PLA General Hospital for National Distinguished Young Scholar Science Fund (2017-JQPY-002). Author contributions: B.Y. and S.H. were responsible for the design and primary technical process, conducted the experiments, collected and analyzed data, and wrote the manuscript. Y.W. and R.W. helped perform the main experiments. Y.Z. and T.H. participated in the 3D printing. W.S. and Z.L. participated in cell experiments and postexamination. S.H. and X.F. collectively oversaw the collection of data and data interpretation and revised the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

See the original post here:
Biochemical and structural cues of 3D-printed matrix synergistically direct MSC differentiation for functional sweat gland regeneration - Science...

Read More...

Lies, Spies and Double Agents: On the Trail of Peter Nygard in the Bahamas – The New York Times

March 8th, 2020 10:43 am

Given Mr. Nygards alleged sway in the Bahamas, we were told we needed to be careful.

We switched hotels every few days so no one could track us. A Courtyard Marriott worker insisted that the hotel could not deny I was staying there if someone asked for me by name, so he disguised me as LaKim LaBarker, a pseudonym that seemed like poor tradecraft.

One source would talk to me only in a car; as he drove us through a wooded area, he said, worryingly: Dont worry. Im not going to kill you. People recorded our conversations without telling us. A man with a spoofed phone number (which hid his actual location and number) called my dad, looking for me. No one ever called my dad looking for me.

Mr. Nygard actively tried to shut down the article. He filed a racketeering lawsuit against Mr. Bacon, accusing him of trying to plant a false story with The New York Times. One of his lawyers called the allegations paid-for lies. Mr. Nygards spokesman falsely suggested that I had taken $55,000 funneled through Mr. Bacons foundation. (The so-called evidence: On a public 2016 tax return for the foundations grants, easily printable from the internet, somebody had scrawled BARKER $55K next to a grant for Media Matters.)

Weeks before we first hoped to publish, we doubled down on our interviews, visiting our sources to corroborate their stories and crosschecking for inconsistencies. We found that Mr. Smith and his team had spread more money around than anyone had previously told us; in particular, they had paid two women who had helped find alleged victims.

Reporting was complicated by the fact that Mr. Smith had recently nearly died in a paragliding accident in Italy, and we had to interview him as he recovered in an Italian hospital. At times, he screamed in pain.

Then a reporters worst nightmare happened: Two accusers told us they had been lying all along. They said they had never met Mr. Nygard. They claimed they had been paid to lie not by Mr. Smith, not by Mr. Bacon, but by a former Nygard employee, Richette Ross, one of the two women who had helped find victims for Mr. Smith. He had paid her the equivalent of $86,000 a year for her security and to help with another lawsuit against Mr. Nygard, he claimed.

Ms. Ross passed a lie-detector test denying she had paid anyone to lie, the polygraph examiner told us. In December, her Florida lawyer sent me a cease-and-desist letter, threatening to sue if I continued talking about what we had been told.

Original post:
Lies, Spies and Double Agents: On the Trail of Peter Nygard in the Bahamas - The New York Times

Read More...

New daily cases of coronavirus in China fall below 100 in several weeks, death toll now 3070 – Hindustan Times

March 8th, 2020 10:43 am

Chinese health authorities on Saturday said 3070 people had died from the coronavirus outbreak while, for the first time in several weeks, less than 100 new infections were reported from across the country.

The epidemic is showing signs of stabilising in China, especially outside the worst-hit Hubei provinces as it rages globally.

Chinese authorities continued to strictly screen international airports for infected people coming in or returning to China from abroad.

Chinas national health commission (NHC) said Saturday 99 cases were reported from the mainland with 74 of those from Wuhan, Hubei provinces capital, from where the epidemic started in December.

The commission says it is the first time since January 20 that less than 100 people have been found to be infected in one day.

This is the second day that no new case of covid-19 was reported from other parts of the central Chinese province.

All the 28 new deaths on Friday were reported from Hubei, with 21 in Wuhan, bringing the death toll to 3070.

There are now 80,651 infections in mainland China.

According to Wuhans local officials, about one-third of residential communities in the city have had no newly confirmed cases in the past two weeks as of Thursday.

Outside Hubei, nearly all new infections, or at least 24 of those, were found among people coming in to China.

As of Friday, the mainland had reported 60 such cases.

Four people who had travelled to Italy tested positive in Beijing, while in Shanghai a person who had been studying in Iran was found to be infected.

Authorities said 11 out of 311 people who arrived in Gansu Province from Iran on chartered flights between Monday and Thursday also tested positive.

Local governments in Beijing, Shanghai and in the southern province of Guangdong are asking that people arriving from Japan, South Korea, Italy or Iran quarantine themselves at home or elsewhere for 14 days.

Meanwhile, a senior WHO official has said that there is no evidence right now suggesting covid-19 will disappear in summer.

We do not know yet what the activity or behavior of the virus will be in different climatic conditions. We have to assume the virus will continue to have the capacity to spread, Michael Ryan, executive director of the WHO Health Emergencies Program said.

Ryan urged countries to fight the new virus decisively at the current stage and called on countries and societies to avoid blame culture and to do all the things needed to save lives.

Meanwhile, a new study has found that mesenchymal (cells that grow into tissues blood and cartilage) stem cell (MSC) therapy could be effective in treating COVID-19, according to research published in the peer-reviewed journal Aging and Disease, state media reported.

The study, conducted by a research team led by Robert Chunhua Zhao, a professor from Shanghai University and Chinese Academy of Medical Sciences & Peking Union Medical College, assessed clinical outcomes of seven patients treated with MSC therapy at Beijing Youan Hospital for 14 days.

They found that MSCs could greatly optimise the functional outcomes of the patients without observed adverse effects, the china.org reported.

The pulmonary function and symptoms of all patients with covid-19 pneumonia were significantly improved two days after MSCs transplantation. Among them, two moderate and one severe patient were recovered and discharged in 10 days after treatment, the authors wrote in the research paper.

Here is the original post:
New daily cases of coronavirus in China fall below 100 in several weeks, death toll now 3070 - Hindustan Times

Read More...

Man with locked-in syndrome expressed wish not to continue living – The Irish Times

March 8th, 2020 10:43 am

A man developed locked-in syndrome after delayed surgery following a fall from a bicycle, an inquest has heard.

Anthony Mason, from Artane, Dublin 5 was a passenger travelling on the crossbar of a bicycle when the accident happened at Mountjoy Square in Dublin on September 9th, 2002. He was 23 at the time.

Dublin Coroners Court heard Mr Mason hit his head on the footpath as a result of the fall. He displayed no symptoms initially but collapsed less than an hour later at St Stephens Green.

He was on a pushbike with somebody and a car pulled out and he hit his head on the footpath, Mr Masons sister Denise Mason said.

He was rushed to St Jamess Hospital. A CT scan revealed a blot clot on his brain and he was transferred to Beaumont Hospital for surgery on September 14th, 2002.

The doctor said if he had seen him earlier he could have done more for him, Ms Mason said.

Mr Mason never fully recovered and was diagnosed with locked-in syndrome after surgery.

He returned home to the care of his family where he remained for 16 years before his death.

He never spoke again. Mam came up with an alphabet to communicate with him. He couldnt move, only his eyes, head and thumbs, Ms Mason said.

Mr Mason communicated using his eyes and computer technology, the inquest heard. He was cared for by family and visited regularly by friends. He enjoyed following football and watching comedies on TV.

Ms Mason became his primary carer following the death of their father in 2005 and mother in 2013.

Mr Mason had hoped that stem cell research could improve his condition and when this was ruled out he expressed a wish not to continue living. He had a happy life, he was just tired, Ms Mason told the court.

He declined food and water and was assessed by a psychiatrist who found him capable of making this decision. A palliative care plan was put in place and Mr Mason died at home on May 4th, 2018, surrounded by his family, at age 39.

The cause of death was spastic quadriparesis in locked-in syndrome following a fall from a bicycle 16 years previously. Coroner Dr Myra Cullinane returned a narrative verdict tracing the circumstances of death back to the fall.

All of the reports demonstrate that he was very much loved and very well cared [for] and still very much part of the familyhopefully in some way he is at peace now, the coroner said.

Follow this link:
Man with locked-in syndrome expressed wish not to continue living - The Irish Times

Read More...

From Scorpion to Immunotherapy: City of Hope Scientists Repurpose Nature’s Toxin for First-of-Its Kind CAR T Cell Therapy to Treat Brain Tumors -…

March 8th, 2020 10:43 am

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope scientists have developed and tested the first chimeric antigen receptor (CAR) T cell therapy using chlorotoxin (CLTX), a component of scorpion venom, to direct T cells to target brain tumor cells, according to a preclinical study published today in Science Translational Medicine. The institution has also opened the first in-human clinical trial to use the therapy.

CARs commonly incorporate a monoclonal antibody sequence in their targeting domain, enabling CAR T cells to recognize antigens and kill tumor cells. In contrast, the CLTX-CAR uses a 36-amino acid peptide sequence first isolated from death stalker scorpion venom and now engineered to serve as the CAR recognition domain.

Glioblastoma (GBM), the most common type of brain tumor, is also among the most deadly of human cancers, according to the American Cancer Society. It is particularly difficult to treat because the tumors are disseminated throughout the brain. Efforts to develop immunotherapies, including CAR T cells, for GBM must also contend with a high degree of heterogeneity within these tumors.

For the study, City of Hope researchers used tumor cells in resection samples from a cohort of patients with GBM to compare CLTX binding with expression of antigens currently under investigation as CAR T cell targets, including IL13R2, HER2 and EGFR. They found that CLTX bound to a greater proportion of patient tumors and cells within these tumors.

CLTX binding included the GBM stem-like cells thought to seed tumor recurrence. Consistent with these observations, CLTX-CAR T cells recognized and killed broad populations of GBM cells while ignoring nontumor cells in the brain and other organs. The study team demonstrated that CLTX-directed CAR T cells are highly effective at selectively killing human GBM cells in cell-based assays and in animal models without off-tumor targeting and toxicity.

Our chlorotoxin-incorporating CAR expands the populations of solid tumors potentially targeted by CAR T cell therapy, which is particularly needed for patients with cancers that are difficult to treat such as glioblastoma, said Christine Brown, Ph.D., City of Hopes Heritage Provider Network Professor in Immunotherapy and deputy director of T Cell Therapeutics Research Laboratory. This is a completely new targeting strategy for CAR T therapy with CARs incorporating a recognition structure different from other CARs.

Michael Barish, Ph.D., City of Hope professor and chair of the Department of Developmental and Stem Cell Biology, initiated the development of a CAR using chlorotoxin to target GBM cells. The peptide has been used as an imaging agent to guide GBM resection surgery, and to carry radioisotopes and other therapeutics to GBM tumors.

Much like a scorpion uses toxin components of its venom to target and kill its prey, were using chlorotoxin to direct the T cells to target the tumor cells with the added advantage that the CLTX-CAR T cells are mobile and actively surveilling the brain looking for appropriate targets, Barish said. We are not actually injecting a toxin, but exploiting CLTXs binding properties in the design of the CAR. The idea was to develop a CAR that would target T cells to a wider variety of GBM tumor cells than the other antibody-based CARs.

The notion is that the higher the proportion of tumor cells that one can kill at the beginning of treatment, the greater the probability of slowing down or stopping GBM growth and recurrence, Barish added.

Dongrui Wang, a doctoral candidate in City of Hopes Irell & Manella Graduate School of Biological Sciences, was the lead scientist to establish and optimize the CLTX-CAR T cell platform and to determine that cell surface protein matrix metalloprotease 2 is required for CLTX-CAR T cell activation. He added that while people might think the chlorotoxin is what kills the GBM cells, what actually eradicates them is the tumor-specific binding and activation of the CAR T cells.

Based on the promising findings of this study, the study team intends to bring this therapy to patients diagnosed with GBM with the hope of improving outcomes against this thus far intractable cancer. With recently granted Food and Drug Administration approval to proceed, the first-in-human clinical trial using the CLTX-CAR T cells is now screening potential patients.

This work was supported by the Ben & Catherine Ivy Foundation of Scottsdale, Arizona, and the clinical trial will be supported by The Marcus Foundation of Atlanta.

City of Hope, a recognized leader in CAR T cell therapies for glioblastoma and other cancers, has treated nearly 500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has 29 ongoing CAR T clinical trials, including CAR T trials for HER-2 positive breast cancer that has spread to the brain, and PSCA-positive bone metastatic prostate cancer. It was the first and only cancer center to treat GBM patients with CAR T cells targeting IL13R2, and the first to administer CAR T cell therapy locally in the brain, either by direct injection at the tumor site, through intraventricular infusion into the cerebrospinal fluid, or both. In late 2019, City of Hope opened a first-in-human clinical trial for patients with recurrent glioblastoma combining IL13R2-CAR T cells with checkpoint inhibitors nivolumab, an anti-PD1 antibody, and ipilimumab, blocking the CTLA-4 protein.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is the highest ranked cancer hospital in the West, according to U.S. News & World Reports Best Hospitals: Specialty Ranking. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

See more here:
From Scorpion to Immunotherapy: City of Hope Scientists Repurpose Nature's Toxin for First-of-Its Kind CAR T Cell Therapy to Treat Brain Tumors -...

Read More...

Teenager with rare juvenile arthritis ‘feels trapped’ in the body of an 80-year-old – Gloucestershire Live

March 8th, 2020 10:42 am

Libby Smith should be looking forward to her school prom and preparing to take her GCSEs.

Instead, she feels "trapped" in the body of an 80-year-old and needs two knee cap replacements, thanks to a rare form of juvenile arthritis

According to YorkshireLive , the 16-year-old is constantly in pain from juvenile idiopathic arthritis (JIA), so bad that she has considered undergoing a risky bone marrow transplant in an attempt to 're-set' her immune system.

The condition targets Libby's cartilage, making even the simplest of tasks difficult to complete.

Walking, cutting up food and even brushing her hair are now impossible for Libby- she has to rely on her parents Diane Smith, 40, and Adrian Smith, 45, for help.

JIA is an inflammation of one or more joints in a child under the age of 16 years.

Juvenile means that the child was under 16 when the arthritis started, idiopathic means there is no other explanation for the inflammation in their joints and arthritis means that there is swelling and inflammation in the childs joints.

The child's immune system becomes over-active or poorly controlled.

As a result, it starts to attack the lining of the joint which causes inflammation and swelling. Infection can also be a trigger.

Can be more likely in children with a family history of rheumatoid arthritis or lupus.

Information taken from National Rheumatoid Arthritis Society

The teen wanted to become a professional dancer or swimmer, but her dreams were snatched from her when she was first diagnosed with the condition at just 5 years old.

Libby has suffered with mobility issues, having to undergo a lot of surgeries in her lifetime- including a fusion surgery on her right foot, and having an Ilizarov leg brace fitted; she also needs two knee replacements.

Libby is forced to hobble around her home, 'shuffle' downstairs on her bum and has to go out in a wheelchair as her wrists are too weak to use crutches.

The teen, from West Yorkshire, said: "It feels like I'm trapped in an older person's body, I feel like I'm in a hole that I can't get out of.

"I'm waiting for operations to make life easier that are associated more with grandparents - people in their 70s and 80s - rather than my own age.

"I'm upset all the time and I struggle to sleep at night.It's like constant shooting pains that burn, I just want the knee replacement done as soon as possible.

"I've not completed a single day of highschool and struggled with friends as I think people just don't understand.

"It's been really isolating not going to school.It's been frustrating going through this, you get your hopes up that people with JIA grow out of it but I think it just got worse."

Some people with JIA grow out of' the condition, but Libby has not been so lucky and her health continues to deteriorate.

Mum, Diane, says watching Libby's health continue to deteriorate is "breaking her heart" and she turned to social media for answers and support.

The diet consultant said that Libby had always complained of aching legs but only got a official diagnosis in 2011 after Adrian insisted on taking her to A&E when the tot avoided putting any weight on her right leg.

Diane said: "Libby was absolutely fine as a baby but as she got older she would say to me 'I can't walk' and would say her legs were aching all the time.

"She would complain all the time, we just thought she was downright lazy.

"As she was our first child we didn't have anything to compare her to, we just thought that she had little legs and was tired.

"One Sunday when she was five she hopped round on her left leg all day. Adrian told me to pack a bag and that he was taking her to A&E.

"I told him we couldn't take her there as it wasn't an accident or an emergency but he insisted if she couldn't walk he was taking her."

After a week of blood tests and x-rays, Libby finally received her diagnosis of JIA.

Diane said: "We were told it was a childhood condition that she should grow out of in her teens as she goes through puberty.

"They said if she didn't grow out of it then she would probably grow out of it when she had her first baby because things change with hormones.

"She was measured up for crutches, a wheelchair and a walking frame and had physio organised.

"The only history we have of it in our family is with older people, like everyone's family, nan and grandad had it a bit.

"Felicity (Libby's 10-year-old sister) is the complete opposite of Libby, she's the most active child in the country so we knew there was no problem there.

"If we'd had Felicity first and knew how active a child should be, we would have realised there was something wrong with Libby a lot sooner."

Libby's arthritis only worsened as she got older, leaving her unable to attend secondary school- instead, she battled through the pain to study with tutors at home.

Diane said: "She missed her whole high school life because she was so poorly - since leaving junior school her condition got worse and worse.

"We've had English and maths tutors at home but some days I'd have to turn the tutor round at the door and say she wasn't well enough.

"Some days she would manage an hour and other days she could do two, but not very often."

The teen's physical limitations and absence from school means Libby cannot sit her GCSEs.

However, Diane and business owner Adrian encouraged her passion for make-up and she set up her own make-up artist business last year.

Diane said: "Libby's not able to sit her GCSEs as she's missed far too much school because she just wasn't well enough.

"As parents we've been realistic and thought about what she would be able to do as an adult.

"Libby is really good at make-up artist work so we set up a business for her and recently swapped her English and maths tutors for make-up artist tutors.

"She's had a few clients but since Christmas she's just not been well enough, so we've had to put the business on hold."

Libby is on a lot of medication and has undergone a lot of surgeries to combat her painful symptoms- but none of the treatments appear to be working in the long term.

Business owner, Adrian said: "The consultants describe Libby as 'not following the script'.

"Instead of her body accepting medicines that have been successful for other people, it rejects it.

"Libby was looking into a bone marrow transplant to re-set her immune system not so long ago because they were running out of ideas as far as treating it with normal medications.

"The doctors were very blunt about the risks and said she might not make it, there was a substantial percentage that we'd lose her.

"It wasn't because of the procedure, but because of the bacterial medication she's on that increases the risk of her not coming through the re-setting of her immune system.

"We were on the last family of medicines before Christmas and it started working so she decided she wouldn't go ahead with it."

The family are desperately searching for a medicine or treatment that can help Libby's condition.

Adrian said: "This condition is something you associate with someone who's a lot older - she's having to face issues that 80-year-olds face at the age of 16.

"She hobbles around the house, going up and down stairs she does on her bum."When she walks it's more like a shuffle, a move that older people do, and when we go out she has to use the wheelchair.

"She used to be able to brush her hair but we have to do it now, we also cut her meat up for her before she can eat.

"All these other kids her age are off on school trips and going out with friends after school but Libby can't do that.

"As parents we try and do what we can to spend time with her and make her laugh.

"I've said all along that if there was something overseas I would pay for it, we just want answers.

"Sod the funding, if it makes me bankrupt, I'll pay for it."

Continue reading here:
Teenager with rare juvenile arthritis 'feels trapped' in the body of an 80-year-old - Gloucestershire Live

Read More...

Coronavirus medicine: An arthritis drug could be the answer everyone is looking for – Economic Times

March 8th, 2020 10:42 am

A decade-old drug used to treat inflammation in arthritis patients could be the answer to the world's fears of the coronavirus.

Actemra, an anti-inflammation drug made by Swiss drugmaker Roche, has been approved by the Chinese government to treat severe coronavirus symptoms. This comes at a time when countries around the world are desperately searching for ways to combat the deadly infection.

The Swiss drug maker donated nearly $2 million worth of Actemra to China, its local operations said in a blog post on Monday.

According to reports, 14 serious and critically ill patients treated with existing medicines at a hospital affiliated with the University of Science and Technology of China (USTC) showed positive results.

Since Actemra's approval a decade ago, it has become the go-to drug for inflammatory conditions, including cytokine storms in cancer patients receiving cell therapy.

The Swiss company, for which China is its No. 2 market behind the United States, is also making diagnostic gear to detect the coronavirus.

Currently, there is no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany, and India.

Read the original here:
Coronavirus medicine: An arthritis drug could be the answer everyone is looking for - Economic Times

Read More...

Scorpion venom might be the answer to treating arthritis – here’s how it works – Lancashire Post

March 8th, 2020 10:42 am

Scorpion venom could be used to manage arthritis symptoms in the future, according to new research published in the journal Science Translational Medicine.

Scientists suggest that a protein present in scorpion venom could help alleviate the harmful side effects of steroids used to treat arthritis.

Testing on mice, US researchers found this protein rapidly accumulates in joint cartilages, including the knees, ankles, hips, shoulders and spinal discs. They combined these proteins, known as cystine-dense peptides (CDPs), with a steroid normally used to treat rheumatoid arthritis to create a drug delivery system that targeted only the joints and not the rest of the body.

They found that this method reversed joint inflammation in the rodents, while avoiding steroid exposure to other parts of the body.

A 'safer way' to treat arthritis

The team hope that the findings will help a lot of people, providing a 'safer way' to treat the some 10 million sufferers of arthritic diseases in the UK, and 54 million in the US.

While steroids are used to treat inflammation that causes arthritis, they come with dangerous side effects, including weakening of the bones, high blood pressure and increased risk of infections, which is why they cannot be administered for long periods of time.

Dr Jim Olson, of the Fred Hutchinson Cancer Research Centre in Seattle, US, and the senior scientist in the project, said, For people with multi-joint arthritis, the side effects of controlling the disease can be as bad or worse than the disease itself.

Steroids like to go everywhere in the body except where theyre needed most. This is a strategy to improve arthritis relief with minimal systemic side effects.

The researchers looked at cystine-dense peptides (CDPs), a chemically diverse family of proteins found in the venom of scorpions, spiders and snakes.

Treatment reversed inflammation in the joints without damaging tissue

After analysing 42 CDPs from 20 species, they identified one candidate that accumulated within cartilage tissue in rodents.

The scientists then attached these proteins to triamcinolone acetonide, a steroid treatment for arthritis, and found that it helped concentrate the steroid drug within the cartilage of joints in rats with rheumatoid arthritis.

In rheumatoid arthritis, the body's immune system targets affected joints, which leads to pain and swelling.

The treatment was found to reverse inflammation in the joints without damaging tissues in the thymus and spleen, the two organs often affected by repeated steroid treatments.

Researchers say further studies are required to assess the safety of this drug delivery method in animals over longer periods of time before moving on to human clinical trials.

Emily Girard, staff scientist in Dr Olsons laboratory and one of the studys lead authors, said, "There is more development to be done, but I hope that this work results in a therapeutic that will help a lot of people."

More here:
Scorpion venom might be the answer to treating arthritis - here's how it works - Lancashire Post

Read More...

Scorpion venom protein reverses inflammation in rats with arthritis – New Atlas

March 8th, 2020 10:42 am

They mightn't seem like the most obvious places to look, but the venom of deadly creatures like spiders, snakes and scorpions are an increasingly rich source of medicines for human health. The latest example of this comes from scientists at Fred Hutchinson Cancer Research Center, who have discovered a tiny protein in scorpion venom that could become part of a potent new treatment for arthritis.

While drugs exist to treat inflammation in sufferers of arthritis, a scattergun approach means that the often bring severe side effects. These types of non-targeted steroid treatments sweep through the whole body and while they can act swiftly to relieve inflammation, they can also cause high blood pressure or weight gain, and make it harder for diabetics to manage their condition, to list a few examples.

For people with multijoint arthritis, the side effects of controlling the disease can be as bad or worse than the disease itself, says Dr. Jim Olson, who led the new research. Steroids like to go everywhere in the body except where theyre needed most. This is a strategy to improve arthritis relief with minimal systemic side effects.

This strategy Olson speaks of is the product of more than a decade of toiling away in the lab, searching for proteins in scorpion venom that can be used as the basis for advanced drugs to treat various ailments. Around four years ago while screening dozens of peptides from the venom of scorpions and spiders, he and his team found one that seemed to naturally buildup in the cartilage.

This struck the scientists instantly as a potential way to develop more targeted treatments for arthritis. This led to years of trial and error and more tinkering in the lab, until the researchers came up with a recipe that appears to have the desired effect. It involved pairing this peptide with a steroid called triamcinolone acetonide, a combination that was then tested in rats where it proved capable of concentrating in the joints and reversing inflammation in rats with arthritis. And crucially, it produced no detectable side effects.

Its a pretty simple idea to take a mini-protein that naturally goes to cartilage and attach something to it so that you get targeted delivery of the drug, but it was challenging to accomplish, said Emily Girard, a staff scientist in Olsons lab. We had to learn and adapt the behavior of the mini-protein, the chemical linker and the steroid payload to make a product that would go to cartilage, stay as long as we needed it to, release the drug at the right rate, and have a local but not systemic effect. There is more development to be done, but I hope that this work results in a therapeutic that will help a lot of people.

The scientists note that the treatment is still years away from entering clinical use, but describe the proof of concept as "promising."

The team's research was published in the journal Science Translational Medicine.

Source: Fred Hutchinson Cancer Research Center

Read the rest here:
Scorpion venom protein reverses inflammation in rats with arthritis - New Atlas

Read More...

Hope for better arthritis treatment could be found in scorpion venom – Metro.co.uk

March 8th, 2020 10:42 am

Scorpion venom could mitigate the risks of steroids (Jamras Lamyai / EyeEm Provider: Getty Images)

The key to managing arthritis may be found in scorpion venom.

In a roundabout way, the venom could be used to help elderly people and others suffering with the disease.

Scientists suggest that a protein present in scorpion venom could help mitigate the harmful side effects of steroids used to treat arthritis.

Researchers in the US have found this protein rapidly accumulates in joint cartilages, including the knees, ankles, hips, shoulders, and spinal discs, when administered on mice.

The team combined these proteins, known as cystine-dense peptides (CDPs), with a steroid normally used to treat rheumatoid arthritis to create a drug delivery system that targeted only the joints and not the rest of the body.

They found that this method reversed joint inflammation in the rodents, while avoiding steroid exposure to other parts of the body.

The researchers believe their drug delivery method could be a safer way to treat arthritic diseases, which affect more than 10 million people in the UK.

While steroids are used to treat inflammation that causes arthritis, they come with dangerous side effects, including weakening of the bones, high blood pressure and increased risk of infections, which is why they cannot be administered for long periods of time.

Dr Jim Olson, of the Fred Hutchinson Cancer Research Centre in Seattle, US, and the senior scientist in the project, said: For people with multi-joint arthritis, the side effects of controlling the disease can be as bad or worse than the disease itself.

Steroids like to go everywhere in the body except where theyre needed most. This is a strategy to improve arthritis relief with minimal systemic side effects.

The researchers looked at CDPs, a chemically diverse family of proteins found in the venom of scorpions, spiders and snakes. After analysing 42 CDPs from 20 species, they identified one candidate that accumulated within cartilage tissue in rodents.

The scientists then attached these proteins to triamcinolone acetonide, a steroid treatment for arthritis, and found that it helped concentrate the steroid drug within the cartilage of joints in rats with rheumatoid arthritis.

The treatment was found to reverse inflammation in the joints without damaging tissues in the thymus and spleen, the two organs often affected by repeated steroid treatments.

Researchers say further studies are required to assess the safety of this drug delivery method in animals over longer periods of time before moving on to human clinical trials.

Emily Girard, staff scientist in Dr Olsons laboratory and one of the studys lead authors, said: There is more development to be done, but I hope that this work results in a therapeutic that will help a lot of people.

The findings are published in the journal Science Translational Medicine.

Read the original:
Hope for better arthritis treatment could be found in scorpion venom - Metro.co.uk

Read More...

Page 669«..1020..668669670671..680690..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick